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ABSTRACT
Candida albicans is a major human fungal pathogen. A primary goal in studying
C. albicans virulence is actually to find the ways to undermine it and prevent disease. The
best drug targets are proteins or molecules that are not conserved in humans. For most
antimicrobials against bacteria, fungi, or protozoans, the targets are not virulence factors,
but rather enzymes that are important for basic growth or survival. It is not imperative
that the target be required in all growth conditions, but rather just in the host. An area of
research that has shown promising potential for the discovery of new drug targets in
several microbal pathogens is in phospholipid biosynthesis. In this dissertation, there are
three projects that revolve around studying proteins that may be potential drug targets for
C. albicans. 1) inositol biosynthesis was examined. It has been shown in the pathogens
Mycobacterium tuberculosis and Trypanosoma brucei that de novo inositol biosynthesis
is required for virulence or growth. Therefore, the enzyme required for de novo inositol
synthesis was examined for a role in virulence. 2) The phosphatidylserine (PS) synthase
gene (CHO1) of S. cerevisiae is conserved in other fungi, and is not conserved in humans.
Given that PS is an abundant phospholipid in yeasts, it was hypothesized that it would be
important for virulence in the host. 3) Fungi carry homologs of a fungal-specific
transcription factor, called Opi1p, that has been shown to be involved in regulating
filamentous growth and phospholipid biosynthesis in S. cerevisiae. Its homolog was
examined in C. albicans to determine if it regulated these phenotypes in this pathogen
because filamentous growth is an important virulence factor. If the CaOpi1p protein were
essential for filamentous growth then it might be good drug target as it is not conserved in
humans. All three of these projects revolve around phospholipid biosynthesis in C.
albicans and each has revealed interesting and sometime surprising aspects of the biology
and virulence of this fungus.
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Chapter 1: Background and Introduction
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CLINICAL SIGNIFICANCE OF CANDIDIASIS
Candida albicans is a dimorphic yeast that can exist in a human host as either a
harmless commensal, or as an opportunistic pathogen when the host’s immune system is
impaired. C. albicans is capable of causing host damage (or disease) leading to oral,
vaginal, cutaneous, or systemic candidiasis (20). In patients that are neutropenic, Candida
species are associated with severe and deadly systemic candidiasis with a high mortality
rate (31.8%)(27, 116). In fact, Candida species are the fourth most common cause of
catheter-related bloodstream infections in hospitalized patients in the intensive care unit,
and C. albicans is the most commonly isolated species from these infections, giving rise
to enormous associated personal and economic costs (19).
The rise of immunocompromised individuals in our society has provoked a
significant emergence in the number of patients affected by Candida species. About onethird of episodes of candidaemia occur in the intensive care unit (ICU). Although nonalbicans Candida species, such as C. glabrata, C. krusei, and C. parapsilosis are
observed and some have increased resistance to common antifungals, C. albicans was
still the predominant species, causing up to two-thirds of all cases of invasive candidiasis
(166). In invasive candidiasis, a delayed treatment initiation is associated with an
increased mortality, thus empirical therapy strategies become vitally important.
Two decades ago, the therapeutic possibilities for invasive candidiasis were
limited to amphotericin B and azoles, but with the advent of new antifungal agents, such
as echinocandins (e.g. caspofungin), other therapeutic options have become available
(148). Though only a few caspofungin resistant cases have been identified so far, this
indicates that Candida species could develop more wide-spread resistance to this agent
over time. This dissertation will discuss a new class of proteins that may serve as a source
(i.e. phospholipid biosynthesis) for urgently needed new antifungal drug targets in C.
albicans.
VIRULENCE FACTORS OF C. ALBICANS
Morphogenetic conversions
C. albicans is a polymorphic organism that is capable of converting between yeast,
pseudohyphal, and hyphal forms (Fig 1-1, all tables and figures are in the appendix D).
The conventional view has been that yeast forms are associated with passage through the
blood stream or commensal carriage, whereas hyphal forms were associated with tissue
invasion and developing disease. This was based on evidence showing that mutant forms
2

of C. albicans that were locked into the yeast form are avirulent (98). However, this
concept has been challenged by Braun et al., who found that a TUP1-deficient C. albicans
strain that is constitutively hyperfilamentous is also avirulent in a murine model of
systemic candidiasis (15). So far, the precise nature of the association between fungal
morphogenesis and host invasion is still in debate. However, it is now widely accepted
that the ability to undergo morphogenetic conversion, rather than the morphological form
itself, is the primary determinant of pathogenicity (57).
Adhesion to host cells
Adherence of C. albicans to host cells is seen as an essential early step in
establishing disease. Moreover, C. albicans can also adhere to the surfaces of medical
devices and form biofilms, which are relatively resistant to many common antifungal
agents. The ability to form biofilms exhibits a positive association with the degree of
virulence. There are several adhesion molecules (adhesins) in C. albicans. These
adhesins are part of a structurally related superfamily of fungal adhesins, and in C.
albicans include Hwp1p, Eap1p and the eight known members of the agglutinin-like
sequence (ALS) family of adhesins (72, 94, 157). All of these adhesins are
glycosylphosphatidylinositol (GPI)-anchored proteins that are believed to be cell wall
proteins (GPI-CWPs). The GPI-CWPs all have N-terminal signal peptides for
translocation into the ER, and C-terminal signals that mediate GPI membrane anchor
addition (171). The GPI-anchor is believed to mediate attachment to cell wall glucan
(164). One protein that is not in the GPI-CWP class that was initially described as an
adhesin, Int1p (49, 50), is described in this chapter as well.
Agglutinin-like sequence (ALS) family
The ALS family of C. albicans includes eight genes (ALS1-ALS7, and ALS9) that
encode large cell-surface GPI-CWP adhesins that are primarily involved in host-pathogen
interactions and appear to have differing roles in adhesion and transmigration (72). ALS3
and ALS8 represent a single locus (186). Several of the ALS genes have been
characterized and appear to play roles in virulence. Evidence shows that ALS1transformed Saccharomyces cerevisiae exhibits up to 100-fold greater adherence to
endothelial cells (156). In addition, Als1-deficient C. albicans hyphae exhibit reduced
adhesion to endothelial cells (186). Delayed filamentation of the als1∆/als1∆ mutant and
the flocculation of the strain overexpressing Als1p led to the conclusion that Als1p is
similar to Flo11p of S. cerevisiae (164). Similarly, S. cerevisiae transformed with ALS3
shows increased adhesion (156), while Als3-deficient hyphal forms of C. albicans exhibit
3

defective adhesion to endothelial cells (186). ALS3 is also necessary for biofilm
formation in vitro and it mediates endocytosis by epithelial cells (127, 138). In contrast,
mutational analysis has shown that deletion of ALS5, ALS6, or ALS7 results in increased
adhesion of yeast forms of C. albicans to endothelial cells, suggesting an antiadhesive
role for these proteins (187).
Hyphae cell wall protein (HWP1)
HWP1 encodes a major C. albicans hyphae cell wall protein which is a substrate
of mammalian transglutaminases and could promote the cross-link of the fungus to
epithelial cells. Hwp1p is an important developmentally regulated adhesin and found on
surfaces of germ tubes, but not yeast or pseudohyphal forms of C. albicans. Surface
localization, expression in host tissues and importance in systemic candidiasis have been
rigorously demonstrated for Hwp1 (157, 158, 164). C. albicans hwp1Δ/hwp1Δ mutants
exhibited avirulence whereas HWP1/hwp1Δ or wild-type exhibietd full virulence (164).
Hwp1p is also involved in mating and biofilm formation in vitro and in vivo (35, 127).
Integrin-like protein (INT1)
Int1p is an integrin-like protein not in the GPI-CWP class, but implicated in
adhesion properties which binds to host extracellular matrix protein. Although Int1p has
motifs reminiscent of mammalian integrins, it has been shown to be similar to Bud4p of S.
cerevisiae in primary amino acid sequence, in co-localizing with septins and in
functioning in bud site selection (49, 50). The int1Δ/int1Δ mutant exhibited reduced
mortality compared to the wild-type strain, but increased C. albicans persistence in the
kidney (8).
Extracellular hydrolases
Hydrolase production is known to play a central role in the pathogenicity of
bacteria, protozoa, and pathogenic fungi (150). The production of hydrolases may play
more direct role in contributing to host tissue invasion by digesting host cell membranes
and molecules of the host immune system to enhance invasion and to avoid antimicrobial
attack, respectively (20). C. albicans secretes three major hydrolytic enzymes: secreted
aspartyl proteases (Sap), phospholipases, and lipases. Glucanases and chitinases have
also been identified, but not linked to virulence (150).
Secreted aspartyl proteases (SAPs)
The Sap family contains 10 members, SAP1-10, that are all found extracellularly.
Sap1-8 are secreted into the media, but proteases SAP9 and SAP10 are GPI-anchored and
associated with the cell periphery. Interestingly, all secreted Candida proteases belong to
4

the same class of aspartic proteases. Serine-, metallo-, or cysteine- proteases have not
been identified in pathogenic Candida (20). Saps have been one of the most
comprehensively studied virulence factors. Of the SAPs, Sap2, has been the most
extensively studied. Sap2p has been crystallized, and it is the most abundant secreted
protein in vitro when grown in the presence of protein as the sole source of nitrogen (33,
73). Sap1 to Sap3 are preferentially expressed in acidic pH (also their pH optima for
proteolytic activity), while Sap4 to Sap6 are preferentially made in neutral environments
and are believed to be corregulated with filamentous growth.
Sap1 to Sap3p are
associated with mucosal infection while Sap4 to Sap6 are associated with invasive
disease, although both of the subgroups also are known to have overlapping functions
(123).
C. albicans isolates from patients with vaginal candidiasis were significantly more
proteolytic than isolates from asymptomatic vaginal carriers (37). C. albicans isolates
from HIV-positive women with vaginitis also produced significantly higher levels of
protease than did C. albicans strains isolated from HIV-positive asymptomatic carriers or
HIV-negative subjects with candidal vaginitis (39).
Phospholipase
To date, only two secreted phospholipases have been identified. These
phospholipases are both of the B subfamily and are encoded by the genes PLB1 and
PLB2. In a mouse model of systemic candidiasis, the virulence of C. albicans
plb1∆/plb1∆ mutant, which had only 1% of the extracellular phospholipase B activity of
the wild-type strain, was shown to be significantly attenuated (90). Importantly,
immunogold electron microscopy studies showed that C. albicans secretes
phospholipases during the infectious process (54). The function of phospholipases during
C. albicans infections are not precisely known, but they have been implicated in host cell
penetration and may interact with host signal transduction pathways (150).
Lipase
The first lipase gene LIP1 was cloned in C. albicans in 1997 (47). Nine further
members of this lipase gene family (LIP2 to LIP10) were subsequently cloned and
characterized by Hube and his colleagues (75). These secreted lipases may have functions
other than solely providing nutrients for the cells. However, the roles and functions of
lipases during C. albicans infections remain to be elucidated (20). The LIP8 gene has
been shown to be required for virulence in a mouse model of systemic candidiasis based
on the phenotype of the lip8∆/lip8∆ mutant (48).
5

ANTIFUNGALS AGAINST C. ALBICANS AND OTHER HUMAN PATHOGENS
There are five major classes of antifungals used against fungal infections (43,
53) (Fig 1-5). The total number of approved systemic antifungal drugs was only 14 in
2004 (43). The relatively few classes of antifungal drugs will restrict clinicians’
therapeutic choices and these choices are further reduced by the emergence of drug
resistance (21). The development of new class of drugs will provide combination therapy
more flexibility and may provide better treatment (78). Therefore, new drug targets are
urgently needed.
Polyenes
In the 1950s, Amphotericin B (AmB) was released and has been served as the
standard systemic antifungal therapy (51), but it is often poorly tolerated and associated
with nephrotoxicity. The function of polyene agents is to directly bind to ergosterol which
is the fungal equivalent to cholesterol, and is unique in the fungal cell membrane.
Binding of ergosterol by polyenes alters cell permeability resulting in cell death. The
lipid derivatives of amphotericin B, particularly liposomal amphotericin B (LAmB) may
be less nephrotoxic while maintaining a broad antifungal spectrum.
Flucytosine
In the early 1970s, flucytosine (Ancobon) was released by Valeant
Pharmaceuticals Inc. and became an alternative systemic therapeutic option in addition to
AmB. Flucytosine is a pyrimidine analog that inhibits both DNA synthesis and protein
synthesis in the fungal cell (175). However, the toxicity of this agent and the rapid
development of resistance resulted in limited use for treatment (139).
Azoles
In 1979, the first systemic azole antifungal drug, ketoconazole, was released.
Azoles exert their antifungal activity by blocking the demethylation of lanosterol, thereby
inhibiting ergosterol synthesis (60). Ketoconazole was also used for topical agent because
shampoo and cream formulations of ketoconazole have been available for many years
(151). Ketoconazole was followed chronologically by fluconazole and itraconazole. Each
agent offers a specific antifungal spectrum. Although fluconazole’s target Erg11p or
CYP51 in C. albicans has human homolog huCYP51, the fluconazole was developed as a
drug (136). However, azoles exhibit fungistatic activity and drug resistance, a growing
problem among fungal pathogens including C. albicans. It is particularly problematic in
some other Candida species such as Candida glabrata (89).

6

Allylamines
This class includes naftifine and terbinafine, and inhibit ergosterol synthesis at the
level of squalene epoxidase. They are selective for the fungal enzyme and have a minimal
effect on mammalian cholesterol synthesis. Naftifine, the original member of the
allylamine series, possesses only topical activity, whereas the naftifine analog terbinafine
is active both topically and orally (12). Terbinafine is active against a wide variety of
dermatophytes, molds, and dimorphic fungi in which it exerts a fungicidal action.
However, terbinafine exhibits fungistatic activity against C. albicans and drug resistance
has been observed (113).
Echinocandins
Echinocandins form the newest class of antifungals. Caspofungin (Cancidas) was
released by Merck Inc. in 2001. Micafungin and anidulafungin were released afterward
(43). The spectrum of activity is limited to pathogens that rely on these glucan polymers
and is less than the spectrums of the polyenes or azoles. Echinocandins are semisynthetic
lipopeptides, which inhibit synthesis of β-1,3-glucan, an essential and major fungal cell
wall component (80). Because there is no cell wall in mammalian cells, the
echinocandins are less toxic than polyenes antifungals. For example, caspofungin has
been emerging as first-line therapy for invasive candidiasis due to less toxicity and
fungicytotic activity (184). Caspofungin can kill most Candida and Aspergillus species
(Table 1-1) and only rare resistant strains have been identified. Moreover, Cryptococcus
neoformans is naturally resistant to caspofungin (105). It is highly possible that
susceptible fungi will develop resistance over time as this has been observed to a limited
extent.
PHOSPHOLIPID BIOSYNTHETIC PATHWAYS MAY SERVE AS A GOOD SOURCE
FOR NOVEL ANTIFUNGAL TARGETS IN C. ALBICANS
Phospholipid biosynthesis in yeast
Phospholipid composition
The major phospholipids found in growing cells of S. cerevisiae and C. albicans
are PC, PE, PI, and PS. Phospholipid composition can vary dramatically when culture
conditions (i.e. inositol supplementation or starvation) are altered (81). The total lipid
content of C. albicans was 5% of the dry weight while phospholipids and sterols
represented 1.1% and 1.2% of the dry weight, respectively (104). In an azole-sensitive C.
albicans strain, PE (26.2%) constitutes the major phospholipid, then PS (21.1%), PC
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(15.5%) and PI (7.9%) (100). In the plasma membrane of S. cerevisiae, PS (34%)
constitutes the major phospholipid, then PE (20%), PI (18%), PC(17%) while in the
mitochondria, PC (51%) is major phospholipid, then PE (25%), PI (13%), and PS (1%)
(13).
Genes and enzymes involved in phospholipid biosynthesis
The genes involved in C. albicans phospholipid biosynthesis have not been
studied, however, this fungus has homologs of the genes found to be required for
phospholipid biosynthesis in S. cerevisiae, therefore S. cerevisiae is used as a model with
which to explore the process in C. albicans. There are two main pathways for generating
the aminophospholipids phosphatidylethanolamine (PE), and phosphatidylcholine (PC),
and one pathway each for generating phosphatidylserine (PS) and phosphatidylinositol
(PI) (Fig 1-2). Of all of these enzymes, the PS synthase Cho1p is one of the only ones
that is not conserved in humans. Cho1p is localized to the endoplasmic reticulum (ER),
and catalyzes the formation of PS from the precursors serine and cytidine diphosphatediacylglycerol (CDP-DAG) along with the release of CMP (Fig 1-3A). PS serves as a
precursor for the synthesis of PE and ultimately PC by the de novo aminophospholipid
pathway (Fig 1-2). First PS is decarboxylated to PE by one of two enzymes, Psd1p and
Psd2p (Fig 1-3B). Psd1p and Psd2p are mainly localized in the inner mitochondrial
membrane and Golgi complex membrane, respectively. In the de novo pathway, PE is
then used as a substrate to form PC by two phospholipid methyltransferases, Cho2p and
Opi3p. Three methylations of PE are required to form PC, and Cho2p transfers the first
methyl group to PE to form phosphatidylmonomethylethanolamine (PMME). PMME is
then converted by Opi3p to phosphatidyldimethylethanolamine (PDME) and then PC via
the addition of a second and third methyl groups, respectively. As an alternative
mechanism for making PE and PC, the cells can rely on the Kennedy pathway so long as
exogenous choline or ethanolamine are present as substates (Fig 1-2). The Kennedy
pathway has two branches: CDP-ethanolamine and CDP-choline, which produce PE and
PC, respectively by utilizing exogenous ethanolamine and choline. In the CDPethanolamine pathway, exogenous ethanolamine is converted to phospho-ethanolamine
(Etn-P) by ethanolamine kinase (Eki1p). The Etn-P is converted to CDP-ethanolamine
by phosphoethanolamine cytidylyltransferase (Ect1p). The CDP-ethanolamine is then
finally converted to PE by ethanolaminephosphotransferase (Ept1p). In CDP-choline
pathway, exogenous choline is converted to phospho-ethanolamine (Etn-P) by
ethanolamine kinase (Eki1p). The Etn-P is converted to CDP-ethanolamine by
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phosphoethanolamine cytidylyltransferase (Ect1p). The CDP-ethanolamine then is
converted to PE by ethanolaminephosphotransferase (Ept1p). Though Kennedy pathways
are not major ways of PE and PC production in yeast, they do play roles for phospholipid
biosynthesis.
The phospholipid PI is formed from the precursors inositol and CDP-DAG by
phosphatidylinositol synthase (PIS1) (Fig 1-2). Although there is only one enzyme in
yeast to generate PI, the inositol precuror may come from one of two sources. It can
either be made de novo via a cyclization reaction in which glucose-6-phosphate is
converted to inositol-3-phosphate by the Ino1p enzyme. Inositol-3-phosphate is then
dephosphorylated to inositol by an inositolmonophosphatase encoded by INM1 or INM2.
Alternatively, inositol may be imported from the extracellular environment via the
inositol transporters Itr1p or Itr2p.
Regulation of phospholipid biosynthesis in yeast
The regulation of phospholipid biosynthetic enzymes by inositol has been
extensively studies in S. cerevisiae. The factors that regulate phospholipid biosynthesis
include choline, ethanolamine, and lipids (e.g. phosphatidic acid) (23, 58, 99), but
inositol has the strongest effect. Inositol is the rate limiting reagent in PI biosynthesis and
de novo synthesis rates of inositol do not supply as much inositol for PI biosynthesis as
imported inositol when concentrations are high (i.e 75µM). Thus, addition of inositol to
the medium results in an increase in PI biosynthesis and subsequent decreases in levels of
PC, PE, and PS (23). This is because both PI and PS are made from a common pool of
CDP-DAG. As PI synthesis increases and CDP-DAG is consumed more rapidly for this
branch of the pathway, PS synthesis is decreased and as a result the downstream
aminophospholipids PE and PS are also decreased.
The regulation of the inositol level in the cell is very important, and the rates of
synthesis of most phospholipid biosynthetic genes are controlled by a set of transcription
factors that themselves are regulated by inositol levels. These transcription factors
regulate de novo inositol biosynthesis by controlling expression of the inositol-3phosphate synthase gene, INO1, as well as other genes (24). Ino2p and Ino4p activate the
expression of the genes encoding for inosiol-3-phosphate synthase (INO1) and other
phospholipid biosynthesis genes including CHO1, CHO2, and OPI3, while Opi1p
represses the expression of these genes (Fig 1-2). The Opi1p repressor was named by its
mutant phenotype of overproduction of inositol (59). Opi1p is a leucine zipper protein
with two poly-glutamine rich domains but there is no evidence that this protein binds to
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DNA directly. In the absence of exogenous inositol, Opi1p binds to phosphatidic acid
(PA) in the endoplasmic reticulum (ER), hence its ability to translocate to the nucleus to
interact with Ino2p is limited (99). In the presence of inositol, PA levels are decreased
because PA is a precursor for PI biosynthesis, hence Opi1p is released from the ER and
rapidly translocates to nucleus where it inhibits transcription of genes such as INO1,
CHO1, CHO2, and OPI3. It inhbits transcription by binding to the Ino2p component of
the Ino2-Ino4p heterodimeric transcriptional activator, which is bound at the upstream
activating sequence for inositol biosynthesis (UASINO) located on the promoters of the
above target genes (58). Opi1p has an Ino2p interacting domain, and Ino2p has an Opi1p
interacting domain, and these have been demonstrated by in vitro co-purification
experiments (67, 174).
Moreover, inositol phosphorylceramide (IPC) synthase which utilizes PI to
synthesize sphingolipids, is also regulated by inositol. IPC synthase activity is elevated in
wild-type cells supplemented with inositol (85).
Acquisition of phospholipid metabolite inositol in C. albicans and other human
pathogens
In order to cause an infection, microbes must be able to live and grow inside the
host. This necessitates the acquisition of essential nutrients by the pathogen. The
pathogen must either obtain these nutrients from the host or synthesize the nutrients de
novo from more basic compounds. The biosynthesis of phospholipids is an area that has
received considerable attention both in terms of the insight it may give us regarding host
pathogen interactions as well as the possibility that an understanding of phospholipid
metabolism may help in the identification of new drug targets (172). Phospholipids are
complex molecules that are essential for membrane integrity and intracellular signaling.
The biosynthesis of these compounds requires a complex ordered set of biochemical steps
involving a number of enzymes (58, 169, 172). An area of particular interest to
pathogenic microbiologists is understanding how pathogens acquire basic molecules for
the synthesis of phospholipids (172) such as myo-inositol, serine, choline or
ethanolamine. In the last several years a number studies have been performed to elucidate
the roles that proteins involved in myo-inositol acquisition play in controlling virulence
and/or viability in a several divergent pathogens (25, 108, 109, 118). Several of these
pathogens’ acquisition systems are summarized in Fig 1-3.
Since the roles of virulence of inositol acquisition was described in C. albicans by
our published work (25), we will here briefly review the roles of inositol biosynthesis in
10

virulence of Mycobacterium tuberculosis and Trypanosoma brucei. The prokaryotic
pathogen M. tuberculosis, the causative agent of most cases of tuberculosis, can acquire
inositol via de novo biosynthesis or import from environment. The Mtino1 mutant
exhibited inositol auxotrophy, but only high concentration of inositol (77mM) could
rescue mutant’s growth to wild-type level of growth. In addition, Mtino1 mutant
exhibited avirulence in SCID mice (118). In the parasite T. brucei, which causes fatal
sleeping sickness, the TbINO1 gene was shown to be necessary for inositol biosynthesis,
efficient GPI biosynthesis, and even viability in vitro. The Tbino1 mutants are inviable
due to insufficient GPI production (108, 109).
Since these two very different pathogens both require de novo inositol
biosynthesis to cause disease or grow, it suggests the possibility that other pathogens will
have similar requirements. Thus, in chapter two we will describe a study that explores
whether the fungal pathogen Candida albicans also requires de novo inositol biosynthesis
to cause disease.
Phospholipid biosynthetic enzymes as drug targets in human pathogens
Effective drugs to treat various infectious diseases commonly work by targeting a
pathway or activity that is crucial to the pathogen but not to the host. The target needs to
be essential for pathogen’s survival, and its inhibition should cause a cytotoxic effect
rather than a cytostatic effect. Several groups have been identified phospholipid
biosynthetic pathways as novel drug targets in fungal and parasitic pathogens (102, 182)
(Table 1-2). Hence, the phospholipid biosynthetic pathway might serve as an Achilles’
heel of human pathogens.
This part of the introduction will revolve around examples of phospholipid
biosynthetic enzymes in bacteria, fungi, and parasites that may one day serve as drug
targets. They include IPC synthase, serine-decarboxylase phosphoethanolamine
methyltransferase (SDPM), PC synthase, and PS synthase, which are critical for
pathogens’ growth and have no homologs in human.
Inositol phosphorylceramide (IPC) synthase in fungi and parasite
Sphingolipids play roles as structural components of eukaryotic cellular
membranes. In yeast, as in mammalian cells, the first and apparently rate-limiting step in
sphingolipid metabolism involves the condensation of serine and palmitoyl-CoA in the
endoplasmic reticulum (ER) by serine palmitoyl transferase (SPT) (Fig 1-6). SPT was
shown to have two homologous subunits LCB1 and LCB2, both of which are required for
its activity. A third gene required for optimal SPT activity was identified as TSC3. After
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the initial condensation of serine and palmitoyl-CoA into 3-keto dihydrosphingosine, it is
converted to dihydrosphingosine by the enzyme 3-keto reductase. The reductase was also
identified as TSC10. The next step in yeast sphingolipid synthesis appears to diverge
between yeast and mammalian cells. In yeast, dihydrosphingosine (DHS) is hydroxylated
into phytosphingosine, whereas in mammalian cells, dihydrosphingosine appears to be
acylated to dihydroceramide before its reduction. The next step in yeast sphingolipid
synthesis involves the acylation of the long chain base (LCB), phytosphingosine to
phytoceramide. Ceramides in yeast are next incorporated into complex sphingolipids that
are different from mammalian sphingolipids in that the head group is comprised of an
inositol phosphate (IP) instead of a choline phosphate. PI acts as the donor for inositol
phosphate. The enzyme involved in this step is encoded by Aur1p, an essential protein in
yeast (122). This enzyme is also a target for another fungal toxin called aureobasidin, and
because it is not present in mammalian cells, it has emerged as a potentially important
target for anti-fungal drugs. IPC is further mannosylated in the Golgi to MIPC and MIP2C
by the enzymes Csg1p, Csg2p, and Ipt1p (41).
The fungal inositolphosphotransferase (Ipt1p), which is required for biosynthesis
of mannosyl diinositol phosphorylceramide MIP2C, was first characterized in S.
cerevisiae (42). CaIPT1, a ScIPT1 ortholog encoding the M(IP)2C synthase in C. albicans,
was characterized, but the mutant’s effect on virulence was not assessed (142). Since
CaIPT1 has no mammalian ortholog (145), it could be a potential phospholipid drug
target if CaIPT1 is demonstrated to be required for virulence.
The Del Poeta group demonstrated that the Cryptococcus neoformans IPC
synthase mutant (ipc1∆) exhibited reduced virulence in a rabbit animal model of
cryptococcal meningitis (102). Meanwhile, Denny et al. isolated a functional ortholog of
AUR1 in parasite Leishmania major, causative agent of Leishmaniasis. Expression of this
gene in a mammalian cell line led to the synthesis of an IPC-like species, strongly
indicating that IPC synthase activity was reconstituted. The identification and
characterization of this protozoan IPC synthase, an enzyme with no mammalian
equivalent, will raise the possibility of developing anti-protozoal drugs with minimal
toxic side affects (40).
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Serine Decarboxylase Phosphoethanolamine Methyltransferase (SDPM) in parasite
Parasitic protozoa are surrounded by membrane structures that have different
proportions of phospholipids relative to the membranes of the host. It was shown that
some parasites like Plasmodium falciparum have unique phospholipid metabolic
pathways (172). PC biosynthesis in P. falciparum is of particular interest since it is the
most abundant lipid, accounting for half of the total PLs in parasite membranes. PC and
PE comprise 40-50% and 35-45%, respectively, of the parasite’s total plasma membrane
phospholipid content (172). This is quite different from the plasma membrane of red
blood cells in which it resides, where the concentrations of PC and PE are 30.3% and
26.9%, respectively (141).
Salom-Roig and Vial identified that rationally designed choline analogs can
inhibit Plasmodium de novo PC biosynthesis, and exhibit antimalarial effect. These
compounds also interact with malarial pigment, which could enhance the antimalarial
effect. It is likely that they are dual molecules, exerting their antimalarial activity via two
simultaneous toxic effects on the intracellular intraerythrocytic parasites (172). However,
a potential problem with choline analogs might arise because choline is the precursor of
the neurotransmitter acetylcholine. As an alternative approach, the Mamoum group has
identified a PC biosynthetic enzyme as a possible anti-malarial drug target: serine
decarboxylase phosphoethanolamine methyltransferase (SDPM) encoded by PfPMT gene
(182).
PfPMT is required for optimum PC biosynthesis, but performs an enzymatic
activity that is not conserved in mammals. The synthesis of PC in P. falciparum takes
place via the Kennedy pathway, but phosphocholine for this pathway is supplied by
importing it from the host or by making phosphocholine via the serine-decarboxylase
phosphoethanolamine methyltransferase (SDPM) pathway. The SDPM pathway depends
on the PfPMT enzyme which methylates phosphoethanolamine to phosphocholine (Fig 17). This differs from mammals and yeast where PC is made by the Kennedy pathway
only from imported choline or by the de novo pathway through methylating PE (Fig 1-2).
Disruption of PfPMT function results in a complete loss of the SDPM pathway. This
drop in phosphocholine compromises PC biosynthesis and results in defects in parasite
growth, multiplication, and viability, suggesting this gene plays an important role in the
pathogenesis of intraerythrocytic Plasmodium parasites (182). PfPMT is a member of
PEAMT family of phosphoethanolamine methyltransferase and has no mammalian
homologs. The restricted phylogenetic distribution of this class of enzymes suggests that
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they could be potential targets for the development of drugs to treat malaria and other
parasitic diseases.
Phosphatidylcholine synthase in bacteria
The prokaryotic phospholipid biosynthesis pathway is quite different from
eukaryotic cells. For example, the eukaryotic PC biosynthesis and salvage pathways were
missing in most prokaryotic species. In addition, phospholipid biosynthesis in prokaryotic
cells is divergent among species. For example, there is no salvage pathway for PC
production in E. coli, but a salvage pathway for PC production does exist in Brucella
abortus (30)(Fig 1-8). However, the salvage pathway for PC production between
mammalian cells and B. abortus cells is dramatically different. The mammalian cells use
the Kennedy pathway, where choline is converted to CDP-choline and then DAG and
CDP-choline are used to make PC and CMP. In B. abortus choline and CDP-DAG are
used to generate PC and CMP (Fig 1-8) in the choline dependent pathway. The PcsA
mutant, which lacks this activity, exhibits defective mouse spleen colonization (30).
Therefore, the PC synthase (PcsA) of the B. abortus choline dependent pathway could be
a potential drug target. In fact, there is no PcsA homolog in mammalian cells based on
BLAST searches of the PcsA protein against human proteins. Moreover, phospholipid
methyltransferase (PmtA) of B. abortus which methylates PE to form PC also has no
mammalian homolog. The PmtA mutant also exhibits defective mouse spleen
colonization (30). Conover et al. have demonstrated a similar story in Legionella
pneumophila, a gram-negative respiratory bacteria causing severe pneumonia. L.
pneumophila exhibited two pathways to synthesize PC either by phospholipid Nmethyltransferase (PmtA) or phosphatidylcholine synthase (PcsA), but the latter pathway
was demonstrated predominate. The LpPcsA mutant exhibited defective growth in
marcrophages (31).
Phosphatidylserine synthase in fungi and bacteria
Our lab has demonstrated that phosphatidylserine synthase (CHO1) in C. albicans
is essential for virulence and cell wall integrity (Chapter 3). The Cho1p orthologs in other
organisms were obtained (Table 1-3), but there are no human or mammalian orthologs.
Therefore, Cho1p could be potential drug target.
The biological function of PS has been analyzed in S. cerevisiae. Although PS is a
quantitatively minor phospholipid in most biological membranes, it is important for
specific cellular functions in addition to its structural role in membrane. In addition to the
PE precursor, PS is an enzyme cofactor. The best known role of PS as an enzyme
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cofactor is as a specific activator of protein kinase C (PKC). PKC plays crucial roles in
diverse signal transduction pathways (170). PKC contains a C1 and C2 domain, both are
required for translocation of kinase from cytoplasm to the inner leaflet of the plasma
membrane. The C2 domain is responsible for the binding of PKC to PS in a calciumdependent manner and the specificity for recognition of PS by the enzyme requires the
lipid second messenger diacylglycerol. Another protein that requires PS for its function is
cRaf1 protein kinase. Interaction of Raf-1 with PS promotes the translocation of the
protein to the plasma membrane as well (121).
Politino and Kim demonstrated that PS physically interacted with calcineurin, a
immunosuppressive reagent. The interactions with PS and calcineurin were enhanced by
Ca2+ which implicates a regulatory role for the Ca2+-binding subunit in this process. This
also suggests that Ca2+- and calmodulin-stimulated interactions of calcineurin with acidic
phospholipids may play a role in regulating the substrate specificity of this
multifunctional phosphatase (140). A study also highlighted the importance of lipid
signaling molecules in the development and pathogenicity of clinically important fungi.
In Cryptococcus neoformans, sphingolipid-derived diacylglycerol has been shown to
induce the transcription of the putative virulence factor App1, which inhibits the
phagocytosis of fungal cells by alveolar macrophages, as well as to activate the protein
kinase C Pkc1, which promotes cell-wall stability and increased melanin production
(153).
Recently, Bukata et al. demonstrated that phosphatidylserine synthase (PssA) is
required for optimal virulence in B. abortus. The BaPssA mutant exhibited defective
mouse spleen colonization (18). There is no BaPssA ortholog found in mammalian cells.
Taken together, the results show that phosphatidylserine synthase in fungi, and bacteria
could be potential antimicrobial drug targets.
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APPENDIX A: TABLES AND FIGURES

Table 1- 1. Antifungal spectrum of activity against common fungi.
Table adapted from (43).
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Table 1- 2. Phospholipid biosynthetic genes as potential drug targets in pathogenic
microbes.
Fungus
C. albicans: Candidiasis, Vaginitis, Oral Thrush
product
Mutant virulence
gene
CHO1
Phosphatidylserine
Avirulence in mouse model of systemic
synthase
infection
IPT1
Inositol phosphoryl
N/A (hyphal growth abnormal)
transferase
C. neoformans: Meningitis and Meningo-encephalitis
IPC1
Inositol phosphoryl
Reduced virulence in a rabbit animal
ceramide synthase
model of cryptococcal meningitis
A. nidulans: Aspergillosis
BarA
acyl-CoA-dependent
N/A (Hyphal growth abnormal)
ceramide synthase
LagA

Ceramide synthase

Reference
Unpublished
(142)

(102)

(95)

N/A (Hyphal growth abnormal)

(95)

N/A

(40)

Parasite
Leishmania major: Leishmaniasis
IPCS
Inositol
Phosphorylceramide
Synthase
Plasmodium falciparum: Malaria
PMT
Phosphoethanolamine
methyltransferase

Defects of parasite growth, multiplication, (182)
and viability in erythrocytes

Bacterium
Brucella abortus: Brucellosis
Phosphatidylserine
PssA
synthase
Phospholipid NPmtA
methyltransferase
Phosphatidylcholine
Pcs
synthase

Defective for mouse spleen colonization

(17)

Defective for mouse spleen colonization

(30)

Defective for mouse spleen colonization

(30)

Defective growth in macrophage

(31)

Legionella pneumophila
PcsA

Phosphatidylcholine
synthase
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Table 1- 3. Cho1p amino acid identity between C. albicans and other organisms.
Organism
Candida albicans SC5314
Pichia stipitis CBS 6054
Lodderomyces
elongisporus NRRL YB-4239
Debaryomyces hansenii
Pichia guilliermondii ATCC 6260
Kluyveromyces lactis
Ashbya gossypii ATCC 10895
Vanderwaltozyma polyspora
Saccharomyces cerevisiae YJM789
Candida glabrata
Yarrowia lipolytica
Penicillium marneffei ATCC 18224
Schizosaccharomyces pombe
Sclerotinia sclerotiorum 1980
Botryotinia fuckeliana B05.10
Neurospora crassa OR74A
Pyrenophora tritici-repentis Pt-1C-BFP
Schizosaccharomyces
japonicus yFS275
Podospora anserina
Phaeosphaeria nodorum SN15
Magnaporthe grisea 70-15

Gene
phosphotidylcholine synthase
phosphotidylcholine synthase
CDP-diacylglycerol-serine Ophosphatidyltransferase
DEHA2B15686p
hypothetical protein PGUG_02313
hypothetical protein
AER357Cp
hypothetical protein Kpol_1035p53
phosphatidylserine synthase
hypothetical protein
YALI0D08514p
phosphatidylserine synthase
CDP-diacylglycerol--serine Ophosphatidyltransferase
hypothetical protein SS1G_10973
hypothetical protein BC1G_11334
hypothetical protein NCU02381
phosphatidylserine synthase
CDP-diacylglycerol-serine Ophosphatidyltransferase
unnamed protein product
hypothetical protein SNOG_12017
hypothetical protein MGG_03550

%
100%
81%
76%

E value
1e-157
1e-122
6e-113

73%
72%
65%
61%
62%
61%
60%
58%
57%
54%

4e-109
5e-104
9e-92
1e-87
2e-87
5e-87
3e-86
4e-75
7e-67
3e-64

62%
61%
55%
54%
53%

4e-64
3e-63
8e-63
2e-62
6e-62

54%
51%
52%

7e-62
2e-61
5e-61
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A

B

C

Filamentous forms

Fig 1- 1. Candida albicans can grow in at least three different morphologies.
(A) Yeast. (B) Pseudohyphae. (C) Hypha.
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Fig 1- 2. Phospholipid biosynthetic pathways in S. cerevisiae are used as a model to
explore phospholipid biosynthesis in C. albicans.
The CHO1 gene encodes the only phosphatidylserine (PS) synthase in yeast, and it
forms PS de novo from serine and CDP-diacylglycerol (CDP-DAG). As the de
novo pathway continues PS is decarboxylated by the enzymes PSD1 or PSD2 to
generate phosphatidylethanolamine (PE). PE is methylated by the enzymes OPI3
and CHO2 to make phosphatidylcholine (PC). Phosphatidylinositol (PI) is made in
a separate de novo pathway by PIS1 from CDP-DAG and inositol. The cell may
also generate PE and PC from imported exogenous ethanolamine (Etn) or choline
(Cho) and DAG via the Kennedy Pathway. S. cerevisiae and Candida albicans has
two equally effective mechanisms for obtaining inositol while in the host. It can
either generate inositol de novo through INO1, or it can import it from the host
through ITR1.
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A

C

Dihydrosphingosine 1phosphate lyase (DPL1)
Phosphatidylserine
synthase (CHO1)

B

Phosphatidylserine
PSD1
synthase
PSD2
(CHO1)

Fig 1- 3. Biosynthesis of phospholipids. (A), phosphatidylethanolamine (B), and
phosphoryl-ethanolamine (C).
Refer texts for details. Figures modified from (27, 165) and SGD
(http://www.yeastgenome.org/ ).
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Fig 1- 4. Different pathogens utilize diverse strategies for inositol acquisition.
All three microbes represented in this figure are able to generate inositol (yellow hexagon)
de novo by first converting glucose-6-phosphate (green hexagon-P) to inositol-3phosphate (yellow hexagon-P) via the enzyme inositol-3-phosphate synthase (Ino1p).
Next, an inositol monophosphatase (IMPase) dephosphorylates inositol-3-phosphate to
make inositol. All three microbes have at least some level of inositol transport activity
through one or more inositol transporters. Mycobacterium tuberculosis: This prokaryotic
pathogen is able to both synthesize inositol de novo as well as import inositol from the
environment. However, transport may not be very efficient (as indicated by the dotted
arrow passing through the inositol transporter) since the Mtino1 mutant must be grown in
77mM inositol to allow wild-type levels of growth, and mutants lacking the MtINO1 gene
are avirulent. Trypanosoma brucei: This eukaryotic parasite is able to import inositol
from the environment or synthesize it de novo. However, according to the current model,
inositol imported from the environment is utilized primarily in bulk phosphatidylinositol
(red and yellow phospholipid) production via a phosphatidylinositol synthase (PIS)
localized to the Golgi complex. Inositol synthesized de novo is primarily used to generate
phosphatidylinositol that is used for production of glycosylphosphatidylinositol (GPI).
The de novo inositol is believed to be utilized mostly for GPI production because the
IMPase that converts inositol-3-phosphate to inositol is localized to the ER where GPI
synthesis occurs. Mutants lacking TbINO1 are inviable because of diminished GPI
production. Candida albicans: This fungal pathogen can acquire inositol by de novo
synthesis or by importing it, and either mechanism is sufficient to support wild-type
growth in vitro and full virulence. Figure adapted from Reynolds’ unpublished data.
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Fig 1- 5. Targets of systemic antifungal agents. Refer texts for details.
Figure adapted from (43).
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Fig 1- 6. Outline of sphingolipid metabolism in Saccharomyces cerevisiae.
Refer texts for details. Figure adapted from (130).
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Fig 1- 7. Pathways for the biosynthesis of phosphatidylcholine in P. falciparum.
The CDP-choline pathway is shown with gray arrows. The SDPM pathway is depicted
by dotted arrows. PfAAP, amino acid permease; Cho, choline; CDP, cytidine diphosphate;
CDP-cho, CDP-choline; CDP-Etn, CDP-ethanolamine; Hb, hemoglobin; PC,
phosphatidylcholine; PE, phosphatidylethanolamine; PfCCT, P. falciparum CTP
phosphocholine cytidylyltransferase; PfCEPT, P. falciparum choline/ethanolaminephosphate transferase; PfCK, P. falciparum choline kinase; PfCP, P. falciparum choline
permease; PfECT, P. falciparum CTP phosphoethanolamine cytidylyltransferase; PfEK, P.
falciparum ethanolamine kinase; PfPMT, P. falciparum phosphoethanolamine
methyltransferase; PPM, parasite plasmamembrane; PVM, parasitophorous vacuolar
membrane; RBC, red blood cell; RBCM, red blood cell membrane; PfSD, serine
decarboxylase; Ser, serine; SAM, S-adenosyl-L-methionine. Figure adapted from (182).
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Fig 1- 8. Possible phospholipid biosynthetic pathways in prokaryotic Brucella abortus
and Legionella pneumophila.
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Chapter 2: Candida albicans uses multiple mechanisms to acquire the essential
metabolite inositol during infection

This work is lightly adapted from Publication citation: Infection and Immunity. 2008.
June p.2793-2801 coined by Ying-Lien Chen, Sarah Kauffman and Todd B. Reynolds
Department of Microbiology, University of Tennessee, Knoxville, TN 37996, USA
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ABSTRACT

Candida albicans is an important cause of life-threatening systemic bloodstream
infections in immunocompromised patients. In order to cause infections C. albicans must
be able to synthesize the essential metabolite inositol or acquire it from the host. Based
on its similarity to Saccharomyces cerevisiae it was predicted that C. albicans may
generate inositol de novo, import it from the environment, or both. The C. albicans
inositol synthesis gene INO1 and inositol transporter gene ITR1 were each disrupted. The
ino1∆/ino1∆ mutant was an inositol auxotroph, and the itr1∆/itr1∆ mutant was unable to
import inositol from the medium. Each of these mutants were fully virulent in a mouse
model of systemic infection. It was not possible to generate an ino1/ino1∆ itr1∆/itr1∆
double mutant suggesting that in the absence of these two genes C. albicans could not
acquire inositol and was inviable. A conditional double mutant was created by replacing
the remaining wild-type allele of ITR1 in an ino1∆/ino1∆ itr1∆/ITR1 strain with a
conditionally expressed allele of ITR1 driven from the repressible MET3 promoter. The
resulting ino1∆/ino1∆ itr1∆/P MET3::ITR1 strain was found to be inviable in medium
containing methionine and cysteine (which represses the P MET3 promoter), and it was
avirulent in the mouse model of systemic candidiasis. These results suggest a model in
which Candida albicans has two equally effective mechanisms for obtaining inositol
while in the host. It can either generate inositol de novo through Ino1p, or it can import it
from the host through Itr1p.
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INTRODUCTION
Candida albicans is a dimorphic yeast that can exist in a human host as either a
harmless commensal, or as an opportunistic pathogen when the host’s immune system is
impaired (20). In patients that are neutropenic, Candida species are associated with
severe and deadly systemic bloodstream infections with a high mortality rate (31.8%)
(116). In fact, Candida species are the fourth most common cause of catheter-related
blood stream infections in hospitalized patients in the intensive care unit, and C. albicans
is the most commonly isolated species from these infections (19).
The ability of any pathogenic microbe to cause an infection depends on the
organism’s ability to acquire or generate essential nutrients during residence within the
host. There are several examples of auxotrophies that compromise virulence in C.
albicans (82). The most notable example is the defect in uracil biosynthesis caused by a
mutation in URA3. Homozygous URA3 mutants (ura3∆/ura3∆) block the ability of C.
albicans to grow without uridine supplementation and lead to avirulence. In fact, the
level of URA3-encoded orotidine 5'-monophosphate decarboxylase activity can be
correlated with growth and virulence (88). Homozygous mutations in the ADE2 gene,
which blocks the ability of C. albicans to grow in minimal medium or serum in the
absence of exogenous adenine also diminish virulence (45). The homozygous mutations
in the HEM3 gene leading to heme auxotrophy compromise virulence (82). In addition,
an induced temperature-sensitive serine auxotroph was significantly less virulent than the
parent strain (106).
In contrast to these results, auxotrophies for a number of amino acids including
serine, lysine, leucine, histidine, and arginine do not appear to compromise virulence
(106, 128, 155). For example, Noble and Johnson (128) demonstrated that C. albicans
his1∆/his1∆, his1∆/his1∆ leu2∆/leu2∆, and his1∆/his1∆ arg4∆/arg4∆ auxotrophic
mutants exhibited wild-type virulence in a mouse model of systemic candidiasis, whereas
his1∆/his1∆ leu2∆/leu2∆ arg4∆/arg4∆ triply auxotrophic strains were only mildly
attenuated in virulence compared to the wild-type. These results suggest that there are
some metabolites such as amino acids that C. albicans can scavenge from the host during
an infection, while there are other metabolites that it must make de novo such as uracil,
adenine, and heme.
Myo-inositol (referred to here as inositol) is essential for the growth of all
eukaryotes, and is needed by some bacteria (63). Inositol is involved in many
intracellular processes including growth regulation, membrane structure, osmotolerance,
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signal transduction, and the formation of glycosylphosphatidylinositol (GPI)-anchored
proteins, which are themselves essential (11, 24, 133, 161). Inositol has been implicated
in the pathogenicity of C. albicans because it is an essential precursor for
phospholipomannan, a GPI-anchored glycolipid on the cell surface of Candida which is
involved in pathogenicity (115).
There are three potential sources of inositol available to C. albicans based on
work that has been done in the related yeast S. cerevisiae: 1) de novo biosynthesis, where
glucose 6-phosphate is converted to inositol 1-phosphate by the inositol-1-phosphate
synthase enzyme; 2) inositol import from the extracellular environment by an inositol
transporter; and 3) recycling of inositol from the dephosphorylation of inositol
polyphosphate products (24, 125, 161).
In S. cerevisiae, de novo inositol biosynthesis and import have both been well
studied. The S. cerevisiae inositol 1-phosphate synthase is encoded by the INO1 gene
(44). The Ino1p enzyme converts glucose-6-phosphate to inositol-1-phosphate, and then a
second enzyme, inositol monophosphatase, encoded by the INM1 gene, dephosphorylates
inositol-1-phosphate to create inositol (101). S. cerevisiae carries two distinct inositol
transporter genes, ScITR1 and ScITR2, which are both capable of importing inositol, but
at different efficiencies (126).
C. albicans carries a putative homolog of INO1 based on sequence similarity
which was identified and sequenced by Klig et al (Genbank accession #L22737) (83, 84).
C. albicans INO1 shows 64% identity to S. cerevisiae INO1 at the amino acid level (84).
In addition, it has been shown that C. albicans has a potent inositol transporter activity
(77). It was demonstrated that the inositol transporter in C. albicans has an apparent Km
value of 240±15 µM, which appears to be active and energy-dependent (77). C. albicans
inositol transport activity differs in substrate and cotransporter specificity from the human
inositol-Na+ transporter. However, the inositol transporter gene in C. albicans was not
identified in this previous study.
Recently, the importance of inositol biosynthesis in some human infectious agents
was demonstrated by reports in two unrelated pathogens, Mycobacterium tuberculosis
and Trypanosoma brucei. In T. brucei its INO1 homolog was shown to be necessary for
inositol biosynthesis, efficient GPI synthesis, and growth in vitro (108, 109). In M.
tuberculosis, it was found that its INO1 homolog was required for de novo inositol
biosynthesis and full virulence in a mouse model of infection (118).
It is unknown what roles inositol import or biosynthesis play in the virulence of C.
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albicans. This fungus may be able to both synthesize and import inositol. It became of
interest to determine if C. albicans would behave like M. tuberculosis and T. brucei and
require INO1 function for virulence/viability, or if in contrast to these pathogens, C.
albicans would be able to utilize either de novo synthesis or inositol import to support
virulence.
MATERIALS AND METHODS
Strains and growth media
C. albicans strains and plasmids used in this study are shown in Table 2-1 and
Table 2-2 (see all tables and figures in the appendix A). Media used in this study include
YPD (yeast extract-peptone-dextrose, 1% yeast extract, 2% peptone, 2% glucose) (163),
defined medium 199 (M199, Invitrogen), yeast carbon base-bovine serum albumin
(YCB-BSA) (154), and minimal medium (MM, 0.67% Difco yeast nitrogen base without
amino acids, 2% glucose) (163). MM medium was supplemented with 75 µM inositol for
supporting the growth of the C. albicans ino1∆/ino1∆ mutant and 2.5mM methionine and
cysteine for MET3 promoter shutoff assays (22). Inositol-free media (163) was made for
testing the phenotype of the ino1∆/ino1∆ mutant. Agar plates were solidified with 2%
agar (granulated, Fisher) for YPD and with 2% BactoAgar (contains no residual inositol)
for MM and inositol-free media.
Strain construction
The C. albicans INO1 gene (INO1) was disrupted by using the CaNAT1-FLP
cassette (154), whereas, the C. albicans ITR1 gene (ITR1) was disrupted by using the
SAT1 flipper (143).
For the INO1 disruption construct, the 564 basepair (bp) 5’ non-coding region
(NCR) of INO1 was amplified with primers JCO39 and JCO40 (Table 2-3), which
introduced KpnI and ApaI restriction sites, and was cloned into pJK863 5’ of the
CaNAT1-FLP cassette (Fig 2-1A). The 583bp 3’ NCR of INO1 was amplified with
primers JCO41 and JCO42 which introduced SacII and SacI sites, and was cloned into
pJK863 3’ of the CaNAT1-FLP cassette (Fig 2-1A). This created the INO1 knock out
construct plasmid pYLC94 (Table 2-2, Fig 2-1A), which was cut with KpnI and SacI to
release the disruption construct which was transformed into the wild type SC5314 strain
by electroporation as described previously (36, 143). The disruption construct was used
to sequentially disrupt both alleles of INO1 as previously described (154). The INO1
reconstitution construct was made by amplifying a 2.1 Kb fragment containing the INO1
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ORF and 5’ NCR from SC5314 genomic DNA using primers (JCO39 and JCO47) that
introduced KpnI and SalI sites. This fragment was ligated into the pRS316 vector along
with a 1.7 Kb fragment containing the NAT1-3’INO1NCR amplified from plasmid pYLC94
using primers JCO50 and JCO42 which introduced SalI and SacI sites. This resulted in
the INO1 reconstitution plasmid pYLC119 (Table 2-2, Fig 2-1B). The 3.8Kb KpnI-SacI
fragment from pYLC119 was transformed into the ino1∆/ino1∆ mutant (YLC113) in
order to create the reconstituted ino1∆/ino1∆::INO1 strain (YLC120).
A similar approach was used to knock out ITR1 with the SAT1 flipper plasmid
pSFS2A (143). Approximately 500 bp 5’ and 3’ NCRs from ITR1 were amplified using
the primer pairs JCO89-JCO90 and JCO93-JCO94, respectively, each of which
introduced restriction sites into the corresponding fragments. The ApaI-XhoI 5’ITR1NCR
and NotI 3’ITR1NCR fragments were ligated into pSFS2A resulting in the ITR1 knock out
construct plasmid pYLC164 (Table 2-2, Fig 2-2A). The 5Kb ApaI-SacII fragment from
pYLC164 was electroporated into SC5314 and used to disrupt both copies of ITR1 by
sequential disruptions (117, 143). For the reconstituted construct, JCO89 and JCO111
primers, which added ApaI and EcoRI sites, were used to amplify a 2Kb fragment
containing the 5’ITR1NCR and ITR1 ORF region, which was used to replace the ApaIEcoRI fragment (containing 5’ ITR1NCR-PMAL2-FLP) in the pYLC164 vector resulting in
pYLC208 (Table 2-2, Fig 2-2B). The 5Kb ApaI-SacII fragment from pYLC208 was used
to reconstitute ITR1 in the itr1∆/∆ mutant (YLC196) strain creating the itr1∆/∆::ITR1
strain (YLC211).
The ITR1 conditional mutant was made as follows. Using SC5314 genomic DNA
as template, primers JCO118 and JCO119 (introduced PstI and NotI sites) were used to
amplify a 1362bp fragment containing the CaMET3 promoter (22), and primers JCO120
and JCO121 (introduced NotI and SacII sites) were used to amplify the ITR1 ORF. These
fragments were used to replace the PstI-SacII fragment in pYLC164, which deleted the 3’
flanking FRT site, resulting in the conditional ITR1 expression construct plasmid
pYLC229 (Table 2-2, Fig 2-2C). The 7.6 Kb ApaI-SacII fragment from pYLC229 was
transformed into the ino1∆/ino1∆ itr1∆/ITR1 strain (YLC184) to create the ino1∆/ino1∆
itr1∆/PMET3::ITR1 conditional strains (YLC261 and YLC266).
Northern blot analysis
Northern blotting for ITR1 expression was performed as described (144) with the
following exceptions. Strains grown in liquid medium 199 at 37°C for 2 hrs were
collected for total RNA extraction by the hot phenol method (144). A PCR product
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containing bps 24-750 of the ITR1 ORF (primers JCO102 and JCO103) was used as a
probe. Expression was normalized against C. albicans ACT1 gene expression probed on
the same membrane. The ACT1 probe was generated with the primers JCO48 and JCO49.
Southern blot analysis
Hybridization conditions for the Southern blot analysis were similar to those for
Northern blot analysis, except that the Techne Hybrigene oven was set to 60°C for the
incubation step, and 42°C and 60°C for washing steps. The cells were grown in liquid
YPD at 30°C overnight. The genomic DNA was extracted using the Winston-Hoffman
method (70) and 20µg of genomic DNA were subjected to Southern blotting. The
genomic DNA of ino1 mutants was cut by AflII and SphI restriction enzymes while the
genomic DNA of itr1 mutants was cut by PstI. PCR products containing the ~500bp 3’
NCR of INO1 (primers JCO41 and JCO42) and 3’NCR of ITR1 (primers JCO93 and
JCO94) were used as probes.
Inositol uptake assays
The inositol uptake assay protocol was adapted in part from a protocol of Jin and
Seyfang (77). The wild type, itr1∆/ITR1, itr1∆/itr1∆, and itr1∆/itr1∆::ITR1 strains were
grown in YPD liquid cultures overnight at 30°C. Cells were diluted to 1 OD600 in YPD,
grown at 30°C, and collected at 5 OD600 by centrifugation at 2,600g for 5 min. Cells were
then washed twice with water at 4°C and resuspended in 2% glucose to a final
concentration of 2x108 cells/ml as determined by a hemacytometer. From this time point
on, cells were kept on ice until used for the actual assay. For the uptake assay, the
reaction mixture (250µl) contained 2% glucose, 40mM citric acid/KH2PO4 (pH5.5),
0.15µM [2-3H] inositol (1 µCi/µl, MP Biomedicals), and 200µM unlabeled inositol
(Alexis Biomedicals). Equal volumes of the reaction and cell mixtures (60µl each) were
warmed to 30°C and mixed for the uptake assay which was performed for 10 minutes at
30°C. As negative controls, mixtures were kept at 0°C (ice) during the 10 minute
incubation. One hundred µl aliquots were removed and transferred to pre-wetted metricel
filters on a vacuum manifold. The filters were washed 4 times each with 1ml ice cold
water. The washed filters were removed and added to liquid scintillation vials for
measurements on a Perkin Elmer TRI-CARB 2900TR scintillation counter. The uptake of
radiolabelled inositol over 10 minutes was calculated and plotted as a function of
incubation temperature.
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Mouse infection studies
Five- to six-week-old male CD1 mice (18 to 20g) from Charles River
Laboratories were used in this study. Mice were housed at five per cage. For infection,
colonies from each C. albicans strain were inoculated into 20ml of YPD or MM media.
Cultures were grown overnight, washed twice with 25ml of sterile water, counted by
hemacytometer, and resuspended at 107 cells per ml in sterile water. The cells were then
plated on YPD to determine the viability. Mice were injected via the tail vein with 0.1ml
of the cell suspension (106 cells) (176), and the course of infection was monitored for up
to 30 days. At least two independent infections were performed for each strain. Survival
was monitored twice daily, and moribund mice were euthanized. All experimental
procedures were carried out according to the NIH guidelines for the ethical treatment of
animals.
Statistics
The statistical analysis was done using Prism 4.0 software (GraphPad Software).
For the mouse model of systemic infection, Kaplan-Meier survival curves were compared
for significance using the Mantel-Haenszel log rank test. Tests for significance of
differences between inositol uptake strains were determined using the two-tailed unpaired
t test. Statistical significance was set at P < 0.05.
RESULTS
The INO1 gene in C. albicans is required for growth in the absence of exogenous
inositol
The C. albicans homolog of the S. cerevisiae INO1 gene (ScINO1) identified by
Klig et al (84) was disrupted in order to determine if it was required for inositol
biosynthesis in C. albicans. The C. albicans INO1 homolog (orf19.7585, which we refer
to as INO1 in this communication) was disrupted by sequentially replacing both alleles of
the gene with the NAT1-FLP cassette which contains the nourseothricin resistance gene
(154). The INO1 disruption construct is diagrammed in Fig 2-1A. The INO1 gene was
reintegrated into the INO1 locus of the homozygous mutant (ino1∆/ino1∆) using the
construct shown in Fig 2-1B to verify linkage of any resulting phenotypes with the
genotype. Wild-type (INO1/INO1), heterozygous (ino1∆/INO1), homozygous
(ino1∆/ino1∆), and reconstituted (ino1∆/ino1∆::INO1) strains were analyzed by PCR
(data not shown) and Southern blotting (Fig 2-1C) to confirm the deletion and
reintegration of the correct genes. The wild-type, ino1∆/INO1, ino1∆/ino1∆, and
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ino1∆/ino1∆::INO1 strains were then compared for growth on medium lacking inositol
(163) to determine if an ino1∆/ino1∆ mutation would compromise the ability of the strain
to grow in the absence of inositol. The ino1∆/ino1∆ strain was unable to grow on inositol
free medium, while the wild-type, heterozygous, and reconstituted strains grew equally
well. As expected, the ino1∆/ino1∆ strain was able to grow as well as the wild-type on
identical solid or liquid media with inositol added (Fig 2-1D and data not shown,
respectively).
The INO1 gene is not required for virulence in C. albicans
The INO1 gene does not appear to be required for virulence in a mouse model of
disseminated candidiasis. The wild-type, ino1∆/INO1, ino1∆/ino1∆::INO1, and two
separately derived ino1∆/ino1∆ strains were tested for virulence in the mouse
disseminated infection model (176). These tests revealed no difference in virulence
between the wild type and ino1 mutant strains (Fig 2-5A).
The ITR1 gene is required for inositol transport in C. albicans
The fact that the ino1∆/∆ mutant can grow on medium containing inositol
supports previous studies that have shown that C. albicans harbors an inositol transporter
(77). A C. albicans homolog of the S. cerevisiae ITR1 and ITR2 transporters was
identified by BLASTing the ScItr1p and ScItr2p protein sequences against the Candida
Genome Database (CGD, http://www.candidagenome.org).
This homolog was
orf19.3526 and is referred to as HGT15 in the CGD, but its alias in CGD is ITR2 . This
gene has never been characterized functionally. Based on our BLAST search using CGD,
C. albicans orf19.3526 is the closest homolog to ScITR1 and ScITR2 and is 51% identical
to both S. cerevisiae transporter genes over its full length (data not shown). C. albicans
orf19.3526 also contained the critical inositol transporter motif (D/E)(R/K)φGR(R/K)
(152). Based on the results described below we will refer to orf19.3526 as ITR1 for the
rest of this paper.
Both alleles of the ITR1 gene were sequentially disrupted by replacing each ORF
with the nourseothricin resistance cassette from the SAT1 flipper (143). The itr1∆
disruption construct is diagrammed in Fig 2-2A. The ITR1 gene was reconstituted in the
itr1∆/itr1∆ strain using the reconstitution construct shown in Fig 2-2B. Gene deletions
and replacements were checked for accuracy using PCR (data not shown) and Southern
blotting (Fig 2-2D). As a further test, Northern blotting revealed that the ITR1 transcript
could only be detected in wild-type (ITR1/ITR1), heterozygous itr1∆/ITR1, and
reconstituted itr1∆/itr1∆::ITR1 strains, but not in the itr1∆/itr1∆ strain (Fig 2-2E).
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Expression was lower in the itr1∆/ITR1 and itr1∆/itr1∆::ITR1 strains presumably because
they contain only one allele of the gene.
Analysis of inositol uptake in the wild-type, itr1∆/ITR1, itr1∆/itr1∆ and
itr1∆/itr1∆::ITR1 strains revealed that ITR1 is required for inositol uptake (Fig 2-3).
Inositol uptake was not detectable at 0˚C [(77) and Fig 2-3], hence this was used as a
control. Inositol uptake was 58-fold higher at 30˚C than at 0˚C in the wild type. In
contrast, inositol uptake in the itr1∆/itr1∆ mutant was only 4-fold higher at 30˚C than at
0˚C, but a two-tailed paired t test analysis revealed that there was no significant
difference in uptake between these two temperatures (P=0.34). The itr1∆/ITR1 mutant
showed decreased inositol import compared to the wild type, and the ITR1 reconstituted
strain restored inositol import to a level similar to that seen in the wild-type.
Inositol uptake in the wild type strain in 200µM inositol was found to be 288
pmol per 5x107 cells during a 10 minute uptake period. Jin and Seyfang showed
approximately 60 pmol per 5 x 107 cells during a single minute uptake (77). The
difference between their data and ours is probably due to saturation of uptake over a 10
minute time course (77).
The ITR1 gene is not required for virulence in C. albicans
The itr1∆/itr1∆ strain does not appear to be any less virulent than the wild type in
a mouse model of systemic candidiasis. The wild-type, itr1∆/ITR1, itr1∆/itr1∆, and
itr1∆/itr1∆::ITR1 strains were compared in the mouse model for disseminated infection.
There was not a significant difference between the virulence of the wild-type and the
itr1∆/itr1∆ strains (Fig 2-5B, P=0.95). The itr1∆/ITR1 mutant behaved like the wild-type
(Fig 2-5B) as well. In the reintegrant strain (itr1∆/itr1∆::ITR1) only half of the mice
succumbed to the infection. This may be due to technical error during the injection or an
uncharacterized mutation within the strain. The fact that the wild-type, itr1∆/ITR1, and
itr1∆/itr1∆ strains were all similarly virulent strongly indicates that a lack of ITR1 does
not impair virulence.
The INO1 and ITR1 genes show synthetic defects in growth and virulence
Although neither ITR1 nor INO1 were required for virulence in a mouse model of
systemic candidiasis, it was possible that each could compensate for loss of the other
during infection since it has been shown that rat serum contains 20-100µM inositol (76,
134) and mouse liver contains approximately 100µM inositol (10). In order to test this
hypothesis an attempt was made to disrupt both genes simultaneously. One allele of ITR1
was disrupted in the ino1∆/∆ strain. However, it was not possible to disrupt the other
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allele of ITR1 suggesting that a double mutant consisting of ino1∆/ino1∆ and itr1∆/itr1∆
was synthetically lethal. Therefore, in the ino1∆/ino1∆ itr1∆/ITR1 strain the promoter of
the remaining wild-type ITR1 allele was replaced with the CaMET3 conditional promoter
(22) using the construct described in Fig 2-2C. When the CaMET3 promoter (PMET3) is
used to replace the promoter of a target gene, it represses transcription of that gene in the
presence of methionine and cysteine in the medium. The correct insertion of the
PMET3::ITR1 allele into the chromosome was confirmed by PCR analysis (data not shown)
and Southern blotting (lane 7, Fig 2-2D). The resulting ino1∆/ino1∆ itr1∆/PMET3::ITR1
strain was tested for growth in minimal medium containing 75µM inositol and either 0 or
2.5mM methionine and cysteine. It was found that unlike the wild-type or the ino1∆/∆
itr1∆/ITR1 strains, two separately derived ino1∆/∆ itr1∆/ PMET3::ITR1 strains failed to
grow in the presence of 2.5 mM methionine and cysteine (Fig 2-4).
The ino1∆/ino1∆ itr1∆/PMET3::ITR1 strain was tested to determine whether its
virulence was affected in a mouse model of systemic candidiasis. Previous work had
indicated that the presence of the PMET3 promoter on the essential gene CaFBA1 could
compromise virulence (147). The methionine in the mouse bloodstream is presumably
able to prevent expression of the CaFBA1 gene sufficiently to compromise growth and
virulence in the mouse. The wild-type, ino1∆/ino1∆ itr1∆/ITR1 and two ino1∆/ino1∆
itr1∆/PMET3::ITR1 strains were compared in the mouse model of systemic candidiasis.
This experiment revealed that the ino1∆/∆ itr1∆/ITR1 strain was attenuated for virulence,
and the ino1∆/ino1∆ itr1∆/PMET3::ITR1 strains were avirulent (Fig 2-5C).
DISCUSSION
The mechanism by which C. albicans acquires the essential metabolite inositol during
an infection has not been explored previously. We have found that C. albicans is able to
generate inositol de novo via the INO1 gene product or import inositol from the
environment via the ITR1 gene product with efficiencies that allow it to establish an
infection regardless of which mechanism is employed. This conclusion only applies to
bloodstream infections as this was the only model tested. This result implies that the
bloodstream content of inositol in mice is sufficient to support an infection even if C.
albicans must acquire inositol solely by importing it. Although our search of the literature
did not reveal the estimated inositol content of mouse serum, the inositol levels found in
rats is 20-100µM (76, 134) and may be comparable to mice and is similar to that found in
humans (61.0±12.4 µM) (86).
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The results found with C. albicans are in contrast to what has been observed in
two important human pathogens, M. tuberculosis and T. brucei, which require de novo
inositol biosynthesis via INO1 homologs in order to be fully virulent (Mt) in mouse
models or viable (Tb) (109, 118). Both of these pathogenic microbes are capable of
importing inositol, but in neither case is import sufficient to allow viability in T. brucei or
virulence in M. tuberculosis. In the case of T. brucei, de novo synthesized inositol is used
to make GPI-anchored proteins, while imported inositol is used very inefficiently for this
purpose (108). GPI-anchored proteins are required for viability in T. brucei (97), so
disruption of INO1 compromises viability. In the case of M. tuberculosis the inositol
transporter is too inefficient to import inositol from the host in order to support infection
(118).
Unlike either of these pathogens Candida albicans possesses an inositol
transporter, encoded by ITR1, that is capable of transporting inositol efficiently enough to
allow full virulence in a mouse model of systemic candidiasis even in the absence of de
novo inositol biosynthesis. In the case of both M. tuberculosis and T. brucei it has been
suggested that the development of selective inhibitors of Ino1p homologs might be an
effective way to generate antimicrobials (108, 118). The data reported in this
communication indicates that this would not be effective in C. albicans as it is fully
virulent even in the absence of its Ino1 enzyme. As an alternative approach, it has been
suggested that toxic inositol analogs that are selectively taken up by the C. albicans
inositol transporter but not by the human inositol-Na+ transporter, could be effective
drugs (77). This may be a possibility, although it needs to be determined which of these
two mechanisms, de novo biosynthesis or import, is used by wild-type C. albicans during
an infection. If import is used extensively, then this approach might work, however since
C. albicans is fully virulent in the absence of ITR1, the development of resistant mutants
lacking Itr1p transporter function could be a problem. Nonetheless, a toxic analog might
be useful in combination with drugs affecting other targets such as an azole or polyene
(2).
Based on our results it appears that Itr1p is the primary and perhaps sole inositol
importer in C. albicans both in vitro and during infection. Disruption of ITR1 greatly
inhibits inositol uptake in vitro (Fig 2-3), and in the absence of INO1 a strain carrying
only the P MET3::ITR1 allele of ITR1 cannot grow in medium containing cysteine and
methionine, even in the presence of 75 µM extracellular inositol (Fig 2-4). The amount of
methionine and cysteine in mouse serum is apparently sufficient to decrease expression
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from the MET3 promoter as well, which is consistent with results using a MET3 driven
form of the C. albicans FBA1 gene (147). Our conclusion that ITR1 is the primary or sole
inositol transporter is consistent with a previous study of C. albicans inositol transport
which concluded that there was one inositol transporter in C. albicans that was
responsible for all, or at least the vast majority of, inositol transport activity (77).
The situation in C. albicans contrasts with S. cerevisiae, which has two inositol
transporters that are expressed at widely different levels (126). In S. cerevisiae, the
ScItr1p transporter is the most highly expressed of the two transporters and accounts for
most of the transport activity. The residual transport activity in S. cerevisiae is carried out
by ScItr2p, which is expressed at much lower levels. Based on BLAST searches of the
Candida Genome Database using ScITR1 or ScITR2 as queries, the C. albicans ITR1
gene was the closest homolog to the S. cerevisiae inositol transporters showing 51%
identity over the whole sequence to either ScITR1 or ScITR2. C. albicans carries at least
one other homolog of the S. cerevisiae inositol transporters that is predicted to have 12
transmembrane domains and the (D/E)(R/K)øGR(R/K) motif typical of inositol
transporters. The predicted protein sequence of this gene (orf19.5447, HGT19) bears 26%
and 27% identity to ScItr1p and ScItr2p, respectively. It is possible that orf19.5447
encodes an inositol transporter, but our results suggest that if so, this other transporter is
expressed at too low of a level to transport inositol efficiently or it is expressed in
different conditions than those tested in our experiments. Alternatively, it is a very low
affinity transporter like that seen in M. tuberculosis (118) or it transports molecule other
than inositol.
Taken together our results indicate that either Ino1p or Itr1p can supply the
inositol requirement during an infection, but a number of questions remain to be
answered. For wild-type C. albicans it is not known whether de novo inositol
biosynthesis or import is utilized during an infection or a combination of both are in
operation. It may be variable depending on the distribution of C. albicans cells within the
host. In addition, it is not known whether de novo synthesis or import is favored during
growth in other host niches such as the gut, the oral mucosa, and the vaginal tract. This
again may be variable depending on the nutrient conditions of the particular host niche
and location of cells within those host sites. Further studies will be required to answer
these questions.
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APPENDIX B: TABLES AND FIGURES

Table 2- 1. C. albicans strains
Strain

Parent

Genotype

Source of
reference

SC5314
Clinical isolate
Prototrophic wild type
(55)
(wild-type)
YLC100
SC5314
ino1Δ::NAT1-FLP/INO1
This study
YLC105
YLC100
ino1Δ/INO1
This study
YLC111
YLC105
ino1Δ/ino1Δ::NAT1-FLP
This study
YLC113
YLC111
ino1Δ/ino1Δ
This study
YLC120
YLC113
ino1Δ/ino1Δ::INO1
This study
YLC101
SC5314
ino1Δ::NAT1-FLP/INO1
This study
YLC108
YLC101
ino1Δ/INO1
This study
YLC126a
YLC108
ino1Δ/ino1Δ::NAT1-FLP
This study
YLC176
SC5314
itr1Δ::SAT1-FLP/ITR1
This study
YLC185
YLC176
itr1Δ/ITR1
This study
YLC192
YLC185
itr1Δ/itr1Δ::SAT1-FLP
This study
YLC196
YLC192
itr1Δ/itr1Δ
This study
YLC211
YLC196
itr1Δ/itr1Δ::ITR1
This study
YLC180
YLC113
ino1Δ/ino1Δ itr1Δ::SAT1-FLP/ITR1
This study
YLC184
YLC180
ino1Δ/ino1Δ itr1Δ/ITR1
This study
YLC261
YLC184
ino1Δ/ino1Δ itr1Δ/SAT1-PMET3-ITR1
This study
YLC181
YLC113
ino1Δ/ino1Δ itr1Δ::SAT1-FLP/ITR1
This study
YLC187
YLC181
ino1Δ/ino1Δ itr1Δ/ITR1
This study
YLC266b
YLC187
ino1Δ/ino1Δ itr1Δ/SAT1-PMET3-ITR1
This study
a
another separately derived ino1Δ/ino1Δ homozygous mutant.
b
another separately derived ino1Δ/ino1Δ itr1Δ/PMET3::ITR1 conditional strain.
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Table 2- 2. Plasmids
Plasmids Characteristics
pJK863
pSFS2A
pYLC94
pYLC119
pYLC164
pYLC208
pYLC229

CaNAT1-FLP cassette carrying nourseothricin resistance gene
SAT1 flipper carrying nourseothricin resistance gene
pJK863 flanked 5’ and 3’ INO1NCR for INO1 gene knock out
INO1 reconstitution construct
pSFS2A flanked 5’ and 3’ ITR1NCR for ITR1 gene knock out
ITR1 reconstitution construct
ITR1 conditional construct controlled by CaMET3 promoter

Source of
reference
(154)
(143)
This study
This study
This study
This study
This study
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Table 2- 3. PCR primers
Primer
JCO39
JCO40
JCO41
JCO42
JCO47
JCO50
TRO369
JCO105
JCO106
JCO89
JCO90
JCO93
JCO94
JCO95
JCO96
JCO100
JCO101
JCO111
JCO118
JCO119
JCO120
JCO121
JCO102
JCO103
TRO562
TRO563
JCO48
JCO49

Use
Disrupt INO1
Disrupt INO1
Disrupt INO1
Disrupt INO1
Restore INO1
Restore INO1
Confirm ino1Δ
Confirm ino1Δ
Confirm ino1Δ
Disrupt ITR1
Disrupt ITR1
Disrupt ITR1
Disrupt ITR1
Confirm itr1Δ
Confirm itr1Δ
Confirm itr1Δ
Confirm itr1Δ
Restore ITR1
ITR1 conditional construct
ITR1 conditional construct
ITR1 conditional construct
ITR1 conditional construct
ITR1 Northern blot probe
ITR1 Northern blot probe
INO1 Northern blot probe
INO1 Northern blot probe
CaACT1 Northern blot probe
CaACT1 Northern blot probe

Sequence (5’  3’)
AAAAAAGGTACCGGGATCAAACAATCTAGACTCAC
AAAAAAGGGCCCAGTTATTTGTTTGTGAAGGAGAT
AAAAAACCGCGGTGTTGCTTTATAGTAATATCGCT
AAAAAAGAGCTCCGACAGCCCATATATTTTAATCG
AAAAGTCGACTGATTATTTGAGAATTCTTTC
AAACGTCGACACTGGATGG
GCACGTCAAGACTGTCAAGG
TTATCTATTGTCAATTTCGCC
TGGGAGTTTAGTGTTTGAGC
AAAAAAGGGCCCCTCAACAAATTGTCGATTAT
AAAAAACTCGAGTTCCCTCAAATCAATACACT
AAAAAAGCGGCCGCCTCAGTCTAGTATACTAAAT
AAAAAAGCGGCCGCTGAAATACTTGAACTGTGTGA
GATTATTAGTTAAACCACTGC
TGAAGGGGGAGATTTTCACT
AAACCCCCACTTGAGTCTAA
TTGATCATTTGACCTCGGCA
AAAAAAGAATTCGAGCTATACGGTTGGTTTCGA
AAAAAACTGCAGAAAACTACGAACAATTGTC
AAAAAAGCGGCCGCGTTTTCTGGGGAGGGTATTT
AAAAAAGCGGCCGCATGGGAAGTTCAACCAATAA
AAAAAACCGCGGCTATACGGTTGGTTTCGATT
ACAATCAAAAGCTACCCCCA
TGGTGTATCTGGTAAAAACCA
GAAAACTCTGTTGTTGAAAAAGATG
TTGTTGGCACGTTCACTTTG
CCAGCTTTCTACGTTTCC
CTGTAACCACGTTCAGAC

44

Fig 2- 1. The INO1 gene was disrupted in C. albicans.
(A) Structure of the INO1 disruption construct. Approximately 500 base pairs of noncoding DNA flanking the 5’ and 3’ ends of the INO1 gene (5’-and 3’-INO1NCR,
respectively) were cloned onto either flank of the CaNAT1-FLP construct (154). The
thick dark arrows represent the FRT target sights of the FLP recombinase. The ball and
stick represents the ACT1 terminator (ACT1t) and the thinner arrow on a raised line
represents the SAP2 promoter (PSAP2). (B) The INO1-NAT1 construct used to reintegrate
INO1 ORF into the ino1∆/∆ mutant. (C) Southern blotting was used to confirm the INO1
disruptions. Lane 1 (wild-type); lane 2 (ino1Δ::NAT1-FLP/INO1), lane 3 (ino1Δ/INO1);
lane 4 (ino1Δ/Δ:: NAT1-FLP); lane 5 (ino1Δ/Δ); lane 6 (ino1Δ/Δ::INO1). (D) The INO1
gene is required for growth in the absence of exogenous inositol. The cells were streaked
onto medium containing either 0 or 75µM inositol and grown for 2 days at 30°C.
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Fig 2- 2. The ITR1 gene was disrupted in C. albicans.
(A) Structure of the ITR1 disruption construct. Approximately 500 base pairs of noncoding DNA flanking the 5’ and 3’ ends of the ITR1 gene (5’-and 3’-ITR1NCR,
respectively) were cloned into the pSFS2A plasmid such that they flanked the SAT1
flipper cassette. The thick dark arrows represent the FRT target sights of the FLP
recombinase. The ball and stick represents the ACT1 terminator (ACT1t) and the thinner
arrow on a raised line represents the MAL2 promoter (PMAL2). (B) The ITR1-SAT1
construct used to reintegrate ITR1 ORF into the itr1∆/∆ mutant. (C) The PMET3::ITR1
construct used to replace the ITR1 allele in the ino1∆/∆ itr1∆/ITR1 strain to generate the
ITR1 conditional allele. (D) Southern blotting was used to confirm the ITR1 disruptions.
Lane 1 (wild-type); lane 2 (itr1Δ::SAT1-FLP/ITR1); lane 3 (itr1Δ/ITR1); lane 4
(itr1Δ/Δ::SAT1-FLP); lane 5 (itr1Δ/Δ); lane 6 (itr1Δ/Δ::ITR1-SAT1); lane 7 (ino1∆/∆
itr1∆/PMET3::ITR1). The itr1∆::SAT1-FLP band (disrupted allele prior to “flipping out”
the SAT1-FLP construct) and itr1∆/itr1∆ ::ITR1-SAT1 band (reintegrated ITR1 marked
with SAT1) ran together on the gel. (E) Northern blotting revealed that the expression of
ITR1 was lost in the itr1∆/itr1∆ mutant, but not the wild-type, heterozygous, and
reconstituted strains. Strains were grown in defined medium 199 for 2hrs at 37°C, and
RNA was isolated, Northern blotted, and probed for ITR1 expression. ITR1 expression
was normalized to ACT1 expression on the same blot.
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Fig 2- 3. The ITR1 gene is required for inositol transport in C. albicans.
The inositol uptake assay revealed that the ability to import 3H-myo-inositol was greatly
reduced in the itr1∆/itr1∆ mutant, whereas the wild-type, heterozygous, and reconstituted
strains exhibited the ability to import inositol. Each strain was assayed at 0˚C (white bars)
and 30˚C (black bars).
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Fig 2- 4. The INO1 and ITR1 genes show synthetic defects in growth on agar plates.
The growth of wild-type, ino1∆/∆ itr1∆/ITR1, and two separately derived ino1∆/∆
itr1∆/PMET3::ITR1 strains were compared in 5-fold serial dilutions on minimal medium
containing 75µM inositol ± 2.5mM methionine and cysteine.
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Fig 2- 5. The INO1 and ITR1 genes show synthetic defects in virulence.
The survival of mice was monitored following intravenous challenge with 106 C.
albicans blastospores. (A) Mice were injected with INO1 mutant strains. Wild-type
(n=10); ino1∆/∆ (YLC113, n=10); ino1∆/∆ (YLC126, n=11); ino1∆/∆::INO1 (n=10). (B)
Mice were injected with ITR1 mutant strains. Wild-type (n=5); itr1∆/ITR1 (n=5); itr1∆/∆
(n=10); itr1∆/∆::ITR1 (n=6). (C) Mice were injected with ino1∆/∆ itr1Δ/PMET3::ITR1
conditional double mutant strains. Wild-type (n=10); ino1∆/∆ itr1∆/ITR1 (n=10);
ino1∆/∆ itr1∆/PMET3::ITR1 (YLC261, n=10); ino1∆/∆ itr1∆/PMET3::ITR1 (YLC266, n=10).
Strains for experiments A and B were pre-grown in YPD before the injection while
strains for experiment C were pre-grown in minimal medium-meth-cys plus 75µM inositol.
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ABSTRACT
Candida albicans is one of the most commonly isolated human fungal pathogens,
especially in immunocompromised patients. There are only a few effective antifungals
available to treat fungal infections, creating an urgent need to identify new drug targets.
The S. cerevisiae phosphatidylserine (PS) synthase, Cho1p, is required for PS synthesis,
and is conserved in fungi, but not mammals. We have found that a C. albicans
cho1∆/cho1∆ mutant lacks detectable PS, and is completely avirulent in a mouse model
of systemic candidiasis. The cho1∆/cho1∆ mutant also exhibits defects in cell wall
integrity, mitochondrial function, and filamentous growth, and it is an ethanolamine and
choline auxotroph. However, its growth in choline supplemented media is extremely poor,
with a doubling time of ~36 hours. PS is a precursor for the de novo synthesis of
phosphatidylethanolamine (PE) via PS decarboxylase, and it was hypothesized that some
of the cho1∆/cho1∆ mutant’s defects might be due to loss of de novo PE biosynthesis. A
psd1∆/psd1∆ psd2∆/psd2∆ double mutant, which lacks PS decarboxylase activity, was
found to exhibit defects in cell wall integrity, mitochondrial function, filamentous growth,
and virulence. However, for all of these phenotypes except filamentous growth, the
psd1∆/psd1∆ psd2∆/psd2∆ mutant was not as defective as the cho1∆/cho1∆ mutant. In
addition, the psd1∆/psd1∆ psd2∆/psd2∆ mutant’s growth in minimal media was rescued
similarly with 1 mM ethanolamine or 10 µM choline. The severe virulence defect of the
cho1∆/cho1∆ mutant is likely due, in part, to a loss of de novo PE biosynthesis, but loss
of PS itself contributes to this phenotype as well. We predict that C. albicans PS synthase
could provide an excellent target for the development of a novel antifungal drug.
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INTRODUCTION
The incidence of human systemic fungal infections has increased dramatically in
the last thirty years. This is based, in part, on an increase in the number of
immunocompromised patients due to conditions such as acquired immunodeficiency
syndrome (AIDS), cancer-related chemotherapy, and leukemia (20, 65). Candida species
are the leading cause of fungal infections in humans and can cause mucosal, cutaneous,
and bloodstream infections. Bloodstream infections are of the greatest concern with a
high associated mortality rate (31.8%) (116).
There are only five main types of antifungals used to combat Candida infections,
and a number of these drugs are limited by emerging drug resistance or toxicity to the
patient (43). Therefore, there is an urgent need to identify new targets for development of
antifungal agents. The lipid ergosterol has served as a very potent drug target in fungi,
and three of the major classes of antifungals work by targeting ergosterol or ergosterol
biosynthesis (43). In particular, the azole and allylamine classes affect ergosterol
biosynthesis (12, 53), and the polyenes target ergosterol in the membrane (46). The key to
the effectiveness of these drugs is that their targets are not conserved in the host.
Phospholipid biosynthesis is an emerging area in which to look for novel drug
targets in a number of pathogens. Although similar phospholipids are found in mammals,
bacteria, protozoans, and fungi (81), the enzymes involved in synthesizing some
phospholipids are not conserved between pathogens and mammals. Some of these
nonconserved enzymes may serve as useful drug targets if they are required for growth or
virulence in the host. In the fungal pathogen Cryptococcus neoformans, inositolphosphoryl ceramide synthase 1 (IPC1) is required for sphingolipid metabolism. This
enzyme is essential for virulence in a rabbit model of infection (102). In the bacterial
pathogen Brucella abortus, the enzymes PcsA or PmtA, both required for
phosphatidylcholine (PC) biosythesis, are necessary for virulence in BALB/c mice (30).
Similarly, phosphatidylethanolamine (PE) biosynthesis in B. abortus, which is dependent
on the phosphatidylserine (PS) synthase (PssA), is required for optimal virulence in a
murine model (18). In the parasite Plasmodium falciparum, a potential novel antimalarial drug target was identified: serine decarboxylase phosphoethanolamine
methyltransferase (SDPM) encoded by PfPMT gene.
This enzyme methylates
phosphoethanolamine (Etn-P) to form phosphocholine (Cho-P), and is required for PC
synthesis in P. falciparum. A pfpmt∆ mutant exhibits defects in parasite growth and
viability, suggesting that this gene plays an important role in the pathogenesis of
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intraerythrocytic Plasmodium parasites (182).
Little research has concentrated on the roles of phospholipid biosynthesis in the
pathogenesis of C. albicans. It has been demonstrated that phospholipomannan, a fungal
mannose inositol phosphate ceramide (MIPC) derived from phospholipids, is required for
virulence in a mouse model of systemic infection (115). In addition, the sphingolipid
biosynthetic gene IPT1 is required for C. albicans to undergo hyphal formation, a
virulence factor, in laboratory culture conditions, but its role in virulence in an animal
model has not been examined (142).
A comparison of the basic pathways for phospholipid biosynthesis between the
well-characterized yeast S. cerevisiae and mammals has revealed a potential target that is
conserved in fungi (81). Although phospholipid biosynthetic pathways in mammals and
yeast share many general characteristics in common, a major difference is found in the
synthesis of PS (Fig 3-1). In yeast PS is synthesized from cytidyldiphosphatediacylglycerol (CDP-DAG) and serine by the enzyme ScCho1p, with the associated
release of cytidylmonophosphate (CMP) (92). In mammals, a very different pair of
enzymes, encoded by PSS1 and PSS2, generate PS by exchanging serine for the head
groups of PC and PE, respectively (9, 160, 162). The Cho1p enzyme was among a
number of enzymes on a comprehensive list of proteins that are conserved among fungi,
but not found in mammals, and is, therefore, considered a potential drug target (16).
PS is normally asymmetrically distributed to the cytoplasmic side of the
membrane bilayer in eukaryotic cells (170). PS is also considered both an end product
and a biosynthetic intermediate, since it is found in eukaryotic cell membranes and serves
as a precursor of PE (81)(Fig 3-1). The first description of PS synthesis mutants in
eukaryotic cells (S. cerevisiae) was 30 years ago. Atkinson and colleagues demonstrated
that Sccho1 mutants were unable to synthesize PS and were auxotrophic for choline or
ethanolamine (4, 5). The enzyme responsible for PS synthesis, and the gene encoding it,
were later isolated (92). The PS synthesis mutant (Sccho1Δ) exhibited slow growth on
nonfermentable carbon sources, mitochondrial abnormalities, and the formation of a high
proportion of petite (respiratory-deficient) cells at lower temperatures (5). Interestingly, a
mutant in the conserved PS synthase of fission yeast Schizosaccharomyces pombe (pps1Δ)
was recently demonstrated to have divergent phenotypes including defects in cell
morphology, cytokinesis, actin cytoskeleton, and cell wall integrity. In addition to those
defects, the pps1Δ mutant is auxotrophic for ethanolamine, but cannot be supported by
choline, even on fermentable carbon sources, unlike a S. cerevisiae Sccho1∆ mutant (112).
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PS is clearly not necessary for viability in either of these fungi, however if its homolog is
necessary for virulence or growth of C. albicans in the host, then CaCho1p may be a
good drug target.
In this report we describe that the cho1Δ/cho1Δ mutant in C. albicans is avirulent
in a mouse model of systemic candidiasis. In addition, the mutant exhibits overlapping,
but distinct phenotypes with PS synthase mutants in S. cerevisiae and S. pombe. The C.
albicans cho1Δ/cho1Δ mutant exhibits defects in cell wall integrity, mitochondrial
function, and is very poorly rescued for growth by supplementation with choline. It is
further demonstrated that many of the defects in the cho1∆/cho1∆ mutant are attributable
to a loss of de novo PE biosythesis, but that the loss of PS itself appears to exacerbate
these problems. This study indicates that C. albicans PS synthase is absolutely necessary
for growth in the host and therefore represents a new potential drug target.
MATERIAL AND METHODS
Strains, chemicals, and growth media
C. albicans strains used in this study are shown in Table S3-1 (see all tables and
figures in the appendix B). The following media were used in this study: 1% yeast
extract-2% peptone-2% glucose (YPD) liquid media and agar plates. YPD plates
containing 250μg/ml nourseothricin was used to select for disruptants. Ethanolamine-free
medium was made using the recipe for inositol-free minimal medium and then adding
back 75μM inositol (163). The following supplements, Cyclosporin A (Alexis Biochem),
FK506 (Tecoland), Paraquat (Sigma), Bovine calf serum (HyClone), Fluconazole (AB
Biodisk), Amphotericin B (Fisher), Hygromycin B (Sigma), Nikkomycin Z (Sigma),
Sodium dodecyl sulfate (SDS; Fisher), Caffeine (Acros Organics), Congo Red (ICN
Biochemicals), Calcofluor white (Polysciences), Cyclophosphamide monohydrate
(Sigma), or Papuamide B (gift from Todd Graham, Vanderbilt University, TN) were
added to media at the concentrations described.
The
phospholipid
standards:
phosphatidylserine
(#830034),
phosphatidylethanolamine
(#850757),
phosphatidylinositol
(#840042),
and
phosphatidylcholine (#850457) were purchased from Avanti Polar Lipids Inc. or provided
by Stephen Wright (Carson-Newman College, TN). Ethanolamine and choline chloride
were purchased from Acros Organics Inc., and Fisher, respectively. Trypan blue & Eosin
Y indicator plates for the mitochondrial dysfunction test included 0.15g KH2PO4, 0.15g
(NH4)2SO4, 0.1g MgSO4 ‧ 7H2O, 0.15g peptone, 0.15g yeast extract, 2g glucose, 1mg
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eosin Y, 1mg trypan blue, and 1.5g agar in 100ml H2O (62, 120).
Strain construction
The first allele of the CHO1 gene was disrupted by using the CaNAT1-FLP
cassette (154), whereas its second allele was disrupted by using the SAT1 flipper (143).
The PSD1 and PSD2 genes were disrupted by using the SAT1 flipper.
For the CHO1 disruption construct, an approximately 500-bp 5’ upstream
noncoding region (NCR) of CHO1 (5’ CHO1NCR) was amplified with primers JCO43 and
JCO44 (Table S3-3), which introduced KpnI and ApaI restriction sites, and was cloned
into pJK863 (154), 5’ of the CaNAT1-FLP cassette using the same enzymes (Fig 3-2A).
An approximately 500-bp 3’ CHO1NCR was amplified with primers JCO45 and JCO46,
which introduced SacII and SacI sites, and was cloned into pJK863 3’ of the CaNAT1FLP cassette using the same enzymes (Fig 3-2A). This procedure created the CHO1
knock out construct plasmid pYLC130 (Table S3-2; Fig 3-2A), which was cut with KpnI
and SacI to release the ~ 5.2kb disruption construct, and the wild type SC5314 strain was
transformed with the disruption construct by electroporation (36). The CaNAT1 construct
could not be flipped out from cho1Δ/cho1Δ::NAT1-FLP strains due to the homozygote
being unable to grow sufficiently in the Yeast Carbon Base-Bovine Serum Albumin
(YCB-BSA) medium used to induce the SAP2 promoter that drives the FLP recombinase
on the CaNAT1-FLP cassette (154). We therefore used a similar cloning strategy as
described above to clone 5’- and 3’- CHO1NCR into the SAT1 flipper (pSFS2A) (143),
resulting in pYLC326 (Table S3-2; Fig 3-2A). See Table S3-3 for appropriate primers,
restriction sites, etc. The disruption construct on pYLC326 was used to disrupt the
second allele of CHO1 in the cho1∆/CHO1 heterozygote, and it was flipped out easily
because the homozygote could grow quite well in YPD induction medium (143). The
CHO1 reconstitution construct was made by amplifying a 1.3kb fragment containing the
CHO1 open reading frame (ORF) and the 5’ NCR from SC5314 genomic DNA by using
primers (JCO43 and JCO169) that introduced KpnI and HindIII sites. This fragment was
ligated into the KpnI-HindIII digested pYLC326 which already contained the
3’CHO1NCR. This procedure resulted in the CHO1 reconstitution plasmid pYLC341
(Table S3-2; Fig 3-2B).
We used a similar approach to knock out PSD1 and PSD2 genes, but only the
SAT1 flipper was used. The primers used to generate each disruption construct are listed
in Table S3-3. The psd1Δ/psd1Δ psd2Δ/psd2Δ double mutant (YLC375) was made by
knocking out the PSD1 gene in the psd2Δ/psd2Δ mutant (YLC271) background.
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Southern blot analysis
The cells were grown in liquid YPD at 30ºC overnight. The genomic DNA was
extracted using the Winston-Hoffman method (70), and 20μg of genomic DNA was
subjected to Southern blotting. The genomic DNA of cho1∆/cho1∆ and psd1Δ/psd1∆
mutants were cut with XhoI, while the genomic DNA of the psd2Δ/psd2∆ mutant was cut
with BamHI. PCR products containing the ~500-bp 3’CHO1NCR (amplified with primers
JCO45 and JCO46), the 3’ PSD1NCR (amplified with primers JCO143 and JCO144), and
the 3’ PSD2NCR (amplified with primers JCO148 and JCO149) were used as probes.
Hybridization conditions were described previously (25).
Phospholipid composition assay
The wild-type and phospholipid biosynthetic mutants were grown in shaking YPD
liquid cultures overnight at 30ºC. Cells were washed twice in sterile water and diluted in
5ml YPD containing 5μCi/ml [32P]-phosphoric acid (MP biomedicals) to an OD600 of 0.4
and grown for 3h at 37ºC at 250 rpm. Cells were harvested by centrifugation, washed
with water, and transferred to screw-capped glass tubes (Corning, 16x100mm). The
simple and efficient phospholipid extraction was adapted, in part, from the protocol of
Hanson and Lester (64). In brief, 3ml of ethanol/H2O (4:1) was added to the cell pellets
and heated in a boiling water bath for 15 minutes. After centrifugation in a table top
centrifuge (1000 x g), the supernatants containing radiolabeled phospholipids were
transferred to fresh screw-capped glass tubes. The remaining cell pellets were extracted
two additional times, using 1ml of ethanol/H2O (4:1) for each extraction. All supernatants
(~ 5ml) were pooled, and N2 gas was used to dry down the phospholipids, which were
then resuspended in 50μl of chloroform/methanol (2:1).
The individual phospholipids were resolved using one-dimensional silica gel thinlayer chromatography (TLC) plates (Whatman). The TLC plate was first incubated in the
oven at 100ºC for 15 min, then prewashed (removing debris) thoroughly by
chloroform/methanol (1:1) through migration on the TLC. The prewashed TLC plate was
dried in the hood for 5 min and then baked in the oven at 100ºC for 15 min. Two µl of
extracted radiolabeled phospholipids were spotted on the TLC plate and developed in
cold chloroform/ethanol/water/triethylamine (30:35:7:35). The phospholipids were
detected and quantitated with a Storm PhosphoImager.
The identity of phospholipids was determined by running the samples with
phospholipid standards PS, PE, PC, and PI, and by mass spectrometry. The primuline
spray [5mg primuline (Sigma) dissolved in 100ml of acetone/water (4:1)] was used to
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visualize the lipid spots under UV light.
Mouse infection studies
Five- to 6-week-old male ICR mice (~ 20g) from Harlan Sprague Dawley were
used in this study. Mice were housed in groups of five per cage. For infection, colonies
from each C. albicans strain were inoculated into 5ml of YPD. Cultures were grown
overnight and washed twice with 10ml of sterile water, and cells were counted by
hemacytometer and resuspended in sterile water at 107 cells per ml. Dilutions of the cells
were plated onto YPD containing 1M sorbitol and incubated at 37ºC for 48h to determine
viability. Mice were injected via the lateral tail vein with 0.1ml of the cell suspension (106
cells), and the course of infection was monitored for up to 42 days. Survival was
monitored twice daily, and moribund mice were euthanized. All experimental procedures
were carried out according to the NIH guidelines for the ethical treatment of animals.
For the immunocompromised mouse model, five- to 6-week-old male ICR mice
(~ 20g) from Harlan Sprague Dawley were intraperitoneally injected with 150mg/kg
cyclophosphamide 5 days and 1 day prior to tail-vein injection with C. albicans
blastospores. The cho1Δ/cho1Δ mutants were injected at 106 cells, while the wild type,
psd1Δ/psd1Δ, and psd1Δ/psd1Δ psd2Δ/psd2Δ double mutants were injected at 104 cells
each (100-fold less than the cho1Δ/cho1Δ mutant). The 100mg/kg cyclophosphamide
treatments were continued by injecting the mice every four days until the experiment was
terminated.
For fungal burden analysis, the kidneys were dissected at day 5 in
immunocompetent and at day 4 in immunocompromised mice in order to determine
fungal burden. The kidneys were weighed, crushed, serial diluted in sterile water, and
plated onto YPD containing 1M sorbitol. The plates were incubated at 37ºC for 48h to
determine CFU per gram of kidney. For histopathological analysis, the kidneys were
excised, halved longitudinally, fixed in 10% phosphate-buffered formalin (Fisher),
embedded, sectioned with a Ridge microtome (Knoxville, TN), and stained with Gomori
methenamine silver (GMS) or hematoxylin and eosin (H&E) by standard protocols.
Growth curve measurement
Overnight cultures were washed twice, diluted in YPD to 0.4 OD600/ml and
grown for 3h at 30 ºC. The log-phase cells were then collected, washed twice, and diluted
into Etn/Cho-free medium supplemented with indicated concentrations of Etn or Cho at
0.1 OD600/ml for growth at 37 ºC with shaking at 250 rpm. The media was buffered to
pH 4.0 with 150 mM HEPES to ensure that C. albicans stayed in yeast form even when
58

higher concentrations of Etn were added since Etn is basic and otherwise induces hyphal
growth. The cell concentration was measured with a spectrophotometer at OD600 at 0, 2, 4,
6, 8, and 24 hours. Afterwards, the concentrations were measured daily for up to 14 days.
Susceptibility to paraquat
For spot dilution tests overnight cultures were washed twice with water, five-fold
diluted, and spotted onto YPD agar plates with or without 10mM paraquat, and grown at
37ºC for 48h. For the quantitative viability test, the cells in liquid culture were diluted
and spotted at ~ 200 cells per plate onto YPD agar plates containing 0, 2, 4, 6, 8, or
10mM paraquat and cultured at 37ºC for 24 ~ 48h. The survival percentage was
calculated by the formula: (CFU of YPD containing paraquat) / (CFU of YPD).
Transmission electron microscopy
Cells growing at log phase were harvested and fixed for electron microscopy
using a modification of a protocol by Wright (183). After harvesting the cells they were
suspended in the primary fixative consisting of 3% glutaraldehyde and 3%
paraformaldehyde in 0.1M phosphate buffer. After five minutes the cells were centrifuged,
then re-suspended in fresh fixative overnight at 4ºC. After primary fixation the cells were
washed in 0.1M phosphate buffer for 10 minutes three times. Cells were washed in 1%
KMnO4 for 5 minutes, centrifuged, and re-suspended in fresh KMnO4 for an additional
90 minutes. Cells were then washed in water for 10 minutes three times, and en-bloc
stained in 1% aqueous uranyl acetate for 60 minutes. Cells were washed in water for 10
minutes three times, and dehydrated in a graded ethanol series at 15 minute intervals.
Final dehydration was accomplished with two changes in fresh 100% ethanol. Cells were
infiltrated with gradually increasing ratios of Spurr resin/ethanol over a 24 hour period.
The final four hours of incubation were in 100% Spurr resin under vacuum. After
changing to fresh Spurr resin, samples were placed in a 68 ºC oven for 24 hours. Thin
sections were cut with a Reichert OMU3 ultramicrotome, mounted on copper grids,
stained with lead citrate, and examined with a Hitachi H800 transmission electron
microscope operating at 75KeV.
Identification of phosphatidylserine by electrospray mass spectrometry
The putative PS spot was scraped from the wild type lane on a TLC plate
(Primuline spray and UV light were applied to visualize lipid spots). The scraped powder
containing the putative PS spot was mixed with 4 ml of Chloroform:Methanol:Water
(5:5:1) in the screw-capped glass tube, vortexed, and incubated on ice for 5 min. After
centrifugation (1000 x g for 5 min), the supernatant containing putative PS was collected
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in a fresh glass tube and dried under N2 gas. Fifty μl of chloroform was used to resuspend
the dried PS. The eluted putative PS was initially confirmed by running one dimensional
TLC along with PS standard, then identified by electrospray mass spectrometry. Negative
electrospray mass spectra were obtained from an ion-trap mass spectrometer (LCQ Deca
XP Plus, ThermoElectronic Corp.) by direct infusion of PS samples into electrospray
ionization (ESI) source at a flow rate of 5 µl/min. The capillary temperature was
maintained at 150ºC. The optimized ESI source conditions listed as follow: -4 V for the
capillary voltage, 4.5 kV for the spray voltage, and 30 V for the tube lens offset. Nitrogen
was used as sheath gas at 5 arbitrary units.
Statistical analysis
This was done using Prism 4.0 software (GraphPad Software). For the mouse
model of systemic infection, Kaplan-Meier survival curves were compared for
significance by using the Mantel-Haenszel log rank test. The significance of differences
in phospholipid composition, fungal burden, growth curve, paraquat susceptibility, and
cell wall thickness between strains was determined using the two-tailed unpaired t test.
Statistical significance was set at a P value of <0.05.
RESULTS
CHO1 is required for phosphatidylserine synthesis in C. albicans
A C. albicans homolog of the S. cerevisiae phosphatidylserine (PS) synthase gene
(CaCHO1, hereinafter referred to as CHO1) was identified by BLASTing the ScCho1p
protein
sequence
against
the
Candida
Genome
Database
(CGD,
http://www.candidagenome.org). This search revealed that C. albicans orf19.677 encodes
the closest homolog of ScCho1p, and these proteins share 61% amino acid identity.
The first allele of the CHO1 gene was disrupted by replacing the ORF with the
nourseothricin resistance cassette, CaNAT1-FLP (154). We were unable to obtain a
cho1∆/cho1∆ homozygous mutant in which CaNAT1-FLP was excised from the second
disrupted allele of the cho1∆/cho1∆::NAT1-FLP strain.
This was because the
homozygote could not grow in the nutrient poor medium (YCB-BSA) required to drive
FLP recombinase expression from SAP2 promoter on this cassette (154). Therefore, the
second allele of the CHO1 gene was disrupted using another nourseothricin resistance
cassette (SAT1 flipper) where FLP recombinase expression is driven by the leaky
CaMAL2 promoter (143) even in YPD medium. The cho1∆ disruption constructs are
diagrammed in Fig 3-2A. The CHO1 gene was reconstituted in the cho1∆/cho1∆ strain
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using the reconstitution construct shown in Fig 3-2B. Gene deletions and replacements
were checked for accuracy using PCR (data not shown) and Southern blotting (Fig 3-2C).
In order to determine if the CHO1 gene product serves as the C. albicans PS
synthase, we tested to see if the cho1∆/cho1∆ mutant failed to generate PS as is seen in a
S. cerevisiae Sccho1∆ mutant (4). Phospholipids were in vivo labeled with 32P-phosphoric
acid, extracted using boiling ethanol:water (4:1) (64), separated by thin layer
chromatography (TLC), and visualized by autoradiography with a phosphorimager (Fig
3-2D). A spot from the wild-type strain, that comigrates with the PS standard, was
missing in the cho1Δ/cho1Δ mutant. This spot, which is found in both the wild-type and
cho1∆/cho1∆::CHO1 reconstituted strain was confirmed to represent PS by mass
spectrometry. The spots representing the PS standard and PS from the wild-type strain
were both eluted from the TLC plate and examined by mass spectrometry. Mass peaks
were observed at 760.85 and 760.69 for the spots representing the PS standard and the
putative wild-type PS, respectively, indicating that the spot in question did represent C.
albicans PS (data not shown). Quantification of the phospholipid spots from TLC plates
(representative shown in Fig 3-2D) revealed that the radioactivity associated with the PS
spot in the cho1∆/cho1∆ mutant was only 3% that found in the wild-type strain (Table 31). This is very similar to the reduction in PS production measured in Sccho1∆ mutants
in S. cerevisiae (92) and is equal to background levels (Table 3-1). As a further test for
the role of CHO1 in making PS in C. albicans, the mutant and wild-type strains were
tested for their resistance to Papuamide B. Papuamide B is a a cytotoxic lipopeptide that
binds PS, and in S. cerevisiae, a genetic screen revealed that the Sccho1∆ mutant, which
lacks PS, is resistant to Papuamide B (137). The C. albicans cho1∆/cho1∆ mutant is
resistant to Papuamide B, while the wild-type and CHO1 reconstituted strains are
sensitive (Fig 3-2E), further indicating that CHO1 encodes the C. albicans PS synthase.
The CHO1 gene is essential for virulence
The virulence of the cho1Δ/cho1Δ mutant was tested in a mouse model of
systemic candidiasis. Outbred ICR mice (Harlan) were injected with 106 blastospores via
the lateral tail vein and monitored for signs of infection. It was found that cho1Δ/cho1Δ
mutants are avirulent, whereas the wild type, cho1Δ/CHO1 (data not shown), and
cho1Δ/cho1Δ::CHO1 reconstituted strains exhibited full virulence (Fig 3-3A). The
difference in virulence was reflected in mouse fungal burdens measured at day 5 by
examination of the kidneys (Fig 3-3C). The fungal burden of cho1Δ/cho1Δ mutants was
(7±3) x 103 CFU/g of kidney while the wild type proliferated ~15-fold better than the
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mutant exhibiting (110±2) x 103 CFU/g of kidney (P<0.0001). Similar survival curves
and fungal burdens were observed in mice that were immunocompromised with
cyclophosphamide. In this case, the mice were injected with 100-fold more blastospores
(106) of cho1Δ/cho1Δ mutants than wild type (104). The cho1Δ/cho1Δ mutant was
avirulent under these conditions as well (Fig S3-1), and by day 14, the mice, despite
being immunocompromised, had cleared the cho1∆/cho1∆ mutant from the kidneys, as
no CFUs could be detected (data not shown).
Histological examination of the kidneys revealed that cho1∆/cho1∆ mutant cells
or hyphae were not observable in the kidneys by Gomori Methenamine Silver (GMS)
staining and there was no detectable damage to kidney tissue (H&E staining after 5d
infection). In contrast, in mice infected with wild type C. albicans, hyphae were readily
observed in the kidney and caused considerable necrosis at microscopic (Fig 3-4) and
macroscopic levels (Fig S3-1C).
The cho1Δ/cho1Δ mutant exhibits ethanolamine auxotrophy and very poor growth
in choline
The S. cerevisiae Sccho1∆ mutant is an ethanolamine (Etn) auxotroph because it
lacks PS, which serves as a substrate for the de novo synthesis of
phosphatidylethanolamine (PE). In the de novo synthesis pathway PS is decarboxylated
to PE by two different PS decarboxylase enzymes named ScPsd1p and ScPsd2p (Fig 3-1).
The Sccho1∆ mutant is only able to grow if Etn or Cho are exogenously supplied. The
mutant can make PE via the Etn branch of the Kennedy pathway, and PC by methylating
PE via the de novo pathway (Fig 3-1). Alternatively, if supplied with Cho, the Sccho1∆
mutant can make PC by the Cho branch of the Kennedy pathway, and PE by deriving
phosphoethanolamine (Etn-P) from dihydrosphingosine (DHS) via the DPL1 salvage
pathway (Fig 3-1). However, the ability to use Cho alone is dependent on growth on a
fermentable carbon source. Growth on a non-fermentable carbon source can only be
supported with Etn in the media due to an increased requirement for mitochondrial
respiration (13). Mitochondria are enriched in PE, and PE is important for full
mitochondrial respiratory function (13, 56, 173).
The cho1Δ/cho1Δ mutant is an ethanolamine auxotroph, like the Sccho1∆ mutant
(Fig 3-5A&B), and shows a reduction in its PE level (Table 3-1). Even in medium
containing 1 mM Etn, the cho1∆/cho1∆ mutant did not grow as well as the wild-type (Fig
3-5B), and the doubling time calculated for the wild-type and cho1∆/cho1∆ strains was
~1.6 hours and ~3.3 hours, respectively (Table 3-2). In contrast, the cho1∆/cho1∆ mutant
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could not be rescued on plates by addition of Cho alone to the medium (Fig 3-5A), even
on a fermentable carbon source (glucose). In liquid medium containing Cho alone, there
was no rescue of growth in the first 8 hours of a growth curve, but by 24 hours, there was
some modest growth that eventually became more substantial, but never approached that
of wild-type (Fig 3-5C). The calculated doubling times for the wild-type and
cho1∆/cho1∆ strains in the Cho supplemented medium were ~1.5 hours and ~36 hours,
respectively (Table 3-2). Thus, Cho supplementation allows very little growth in this
mutant. Addition of 100 fold higher levels of Cho (1mM) rescued the mutants only
slightly better than the 10µM shown (Fig 3-5C, and data not shown).
Mutations in PS decarboxylase genes synthesis lead to ethanolamine or choline
auxotrophy
The above results suggested the possibility that the cho1∆/cho1∆ mutant’s
virulence and growth defects were primarily due to a block in the de novo synthesis of PE
by PS decarboxylase activity (Fig 3-1). In order to test this hypothesis, the homologs of
the two S. cerevisiae PS decarboxylase genes ScPSD1 and ScPSD2 were identified by
BLAST searches of their protein sequences against CGD. These homologs, orf19.6045
(CaPSD1, hereinafter called PSD1) and orf19.3954 (CaPSD2, hereinafter called PSD2)
were disrupted using the SAT1 flipper and their genotypes confirmed by PCR (data not
shown) and Southern blot (Fig S3-2). Reconstituted strains were created for each of
these genes as well.
The psd1∆/psd1∆ was found to grow poorly without exogenous Etn (Fig 3-5A),
and it showed a reduction in growth compared to wild-type even when supplemented
with exogenous Etn, although it grew better than the cho1∆/cho1∆ mutant in both liquid
and solid media (Fig 3-5A&B and Table 3-2). The wild-type and psd1∆/psd1∆ mutants
had doubling times of ~1.6 hours and ~2.0 hours in Etn supplemented media, respectively
(Table 3-2). PE production in the psd1∆/psd1∆ mutant was reduced, as it produced only
77% as much as the wild-type strain (Table 3-1)(P=0.005). However, this is higher than
in the cho1∆/cho1∆ mutant, which produced only 60% as much PE as wild-type strain
(Table 3-1). The psd2∆/psd2∆ mutant, in contrast, behaved like wild-type for these
phenotypes (Fig 3-5A and data not shown). The psd1∆/psd1∆ mutant grew much better
than the cho1∆/cho1∆ mutant in media supplemented only with Cho, even in the earlier
parts of the growth curve, although it again grew more slowly than wild-type (Fig 35A&C). The doubling time for the psd1∆/psd1∆ mutant in this medium was ~2.0 hours
compared to 1.5 hours for the wild-type (Table 3-2).
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Although the psd2∆/psd2∆ mutant did not show auxotrophic or growth
phenotypes, the PSD2 gene does appear to affect these phenotypes as a psd1Δ/psd1Δ
psd2Δ/psd2Δ double mutant was more defective for growth than the psd1∆/psd1∆ mutant
in the presence of Cho or Etn (Fig 3-5A-C). The doubling time of the psd1∆/psd1∆
psd2∆/psd2∆ mutant was ~2.3 hours in both types of media (Table 3-2). This phenotype
correlated with a decreased level of PE, as PE in the psd1Δ/psd1Δ psd2Δ/psd2Δ double
mutant was 55% the level of wild-type as compared with 77% in the psd1Δ/psd1Δ single
mutant (Table 3-1). The level observed in the psd1∆/psd1∆ psd2∆/psd2∆ double mutant
is similar to that seen in the cho1∆/cho1∆ mutant (Table 3-1). Interestingly, the PS level
was increased ~two-fold in psd1Δ/psd1Δ psd2Δ/psd2Δ double mutant as compared with
that of wild-type (Table 3-1) (P=0.003). The behavior of the psd1∆/psd1∆ psd2∆/psd2∆
double mutant was somewhat complex compared to the cho1∆/cho1∆ mutant when
growing in medium supplemented with Etn or Cho. In liquid medium supplemented with
Etn or Cho the double mutant had a faster doubling time than the cho1∆/cho1∆ mutant
(Fig 3-5B,C and Table 3-2). However, the double mutant exhibited similar growth
defects to the cho1∆/cho1∆ mutant on agar plates supplemented with Etn or Cho (Fig 35A).
PS decarboxylase genes PSD1 and PSD2 are synthetically required for virulence
Although the psd1∆/psd1∆ and psd1∆/psd1∆ psd2∆/psd2∆ mutants differed in
some respects from the cho1∆/cho1∆ mutants, they exhibited a number of similarities
which suggested that these mutants might affect virulence in the mouse model of
systemic candidiasis. Therefore, mice were challenged with 106 blastospores of the
psd1Δ/psd1Δ or psd2∆/psd2∆ single mutants or the psd1Δ/psd1Δ psd2Δ/psd2Δ double
mutant as previously described. The psd1Δ/psd1Δ and psd2∆/psd2∆ mutants were fully
virulent and behaved like wild-type (Fig 3-3B). In contrast, the psd1Δ/psd1Δ
psd2Δ/psd2Δ double mutant exhibited very attenuated virulence (Fig 3-3B), although it
was more virulent than the cho1∆/cho1∆ mutant as a few mice infected with the double
mutant did succumb to infection whereas no mice infected with the cho1∆/cho1∆ mutant
showed any symptoms of disease (Fig 3-3A). This difference in virulence was reflected
in a two-fold larger fungal burden in the psd1Δ/psd1Δ psd2Δ/psd2Δ double mutant [(15±
0.5) x 103 CFU/g of kidney] compared to the cho1∆/cho1∆ mutant [(7±3) x 103 CFU/g of
kidney] (Fig 3-3C). This difference was not statistically significant, however, a similar
difference was also seen in the cyclophosphamide treated mice (Fig S3-1). In addition,
there was no evidence of C. albicans cells in histological sections of kidneys taken from
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mice infected with the psd1∆/psd1∆ psd2∆/psd2∆ mutant (Fig 3-4). There was also no
sign of infection observed in the kidneys from immunocompromised mice when
examined macroscopically (Fig S3-1C).
Although the psd1∆/psd1∆ mutant exhibited no difference from wild-type in
virulence as measured by the time it took for mice to succumb to the infection (Fig 3-3B),
there was a statistically significant increase in the number of CFU/g of kidney of the
psd1∆/psd1∆ mutant compared to the wild-type strain (P<0.0001, Fig 3-3C).
Defects in PE and PS biosynthesis result in mitochondrial respiration defects
In S. cerevisiae, the loss of PS or PE biosynthesis leads to an increase in the
formation of petite mutants, which are mutants in which the mitochondrial genome has
been lost or the mutants exhibit mitochondrial respiration defects. The increase in petite
formation appears to be due to the fact that mitochondria are enriched for PE, and the
major site of de novo PE synthesis is the inner mitochondrial membrane where ScPsd1p
converts PS to PE. PE is necessary for proper mitochondrial function, and a large
decrease in PE levels correlates with mitochondrial defects and petite formation (5, 13,
28). It was suspected that the mitochondrial respiratory function in the C. albicans
cho1∆/cho1∆ mutant might be compromised. C. albicans is a non-petite forming yeast,
meaning that it cannot survive without an intact mitochondrial genome (3), and defects in
PE or PS biosynthesis may compromise mitochondrial respiration. In order to test this,
the mutants were examined for sensitivity to paraquat. Paraquat is a herbicide that
generates superoxide radicals and oxidative damage in the mitochondria based on its
interactions with complex I and/or alternative NAD(P)H dehydrogenases in the electron
transport chain (29). In S. cerevisiae, mutants that are defective for mitochondrial
respiration show enhanced resistance to paraquat due to decreased electron transport
chain activity (14). In addition, a C. albicans mutant that exhibits decoupling of
oxidative phosphorylation is also more resistant to paraquat (26). Therefore, we
examined the cho1∆/cho1∆, psd1∆/psd1∆, and psd1∆/psd1∆ psd2∆/psd2∆ mutants for
paraquat resistance. All three mutants were clearly more resistant to paraquat based on an
agar dilution assay on plates containing 10 mM paraquat (Fig 3-6A). The psd1∆/psd1∆
psd2∆/psd2∆ mutants did not grow as well as the single mutants on paraquat plates, but
this mutant exhibits poorer growth than that of the single mutants on regular YPD plates,
and it grew better than the wild-type on the paraquat plate (Fig 3-6A). The mutants were
also examined by a more quantitative assay in which cells were pregrown in liquid YPD
medium and then plated at equal concentrations on YPD plates containing 0, 2, 4, 6, 8, or
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10 mM paraquat. The number of colony forming units was then examined. It was found
that the cho1∆/cho1∆ and psd1∆/psd1∆ mutants exhibited a quantitatively similar
resistance to paraquat (Fig 3-6B). The psd1∆/psd1∆ psd2∆/psd2∆ double mutant was not
very resistant based on this assay, but that may be related to its poorer growth on YPD
agar plates and not reflect a lowered resistance. The paraquat resistance exhibited by
these mutants was not due to increased resistance to oxidative stress in general as they
were not hyper-resistant to hydrogen peroxide (Y. -L. Chen and T. B. Reynolds, data not
shown).
The Sccho1∆ mutant has been noted to exhibit a cold-sensitive increase in petite
formation, such that the percentage of cells that loose their mitochondrial genome
increases as the temperature decreases (5). As noted above, C. albicans is petite negative
and presumably loss of the mitochondrial genome is lethal. The cho1∆/cho1∆ mutant
was found to be cold-sensitive for growth. The mutant exhibited decreased growth at
30˚C compared to 37˚C, but was completely unable to grow at 15˚C, even when the assay
was extended out to 4 days (Fig 3-7A). The psd1∆/psd1∆ and psd1∆/psd1∆ psd2∆/psd2∆
mutants also exhibited cold sensitive growth, although the psd1∆/psd1∆ mutant was not
as sensitive as the cho1∆/cho1∆ mutant.
A common test for mitochondrial respiratory deficiency in yeast strains has been
use of the indicator plates containing trypan blue and eosin Y. On these plates mutants
lacking mitochondrial respiratory function take up the dye more readily than wild-type
(62, 120). This assay has been shown to work in C. albicans as well (26, 62). This assay
was performed on the C. albicans phospholipid biosynthetic mutants, and it was found
that all of the mutants took up the dye at greater levels than the wild-type, but there was
an increasing defect indicated in the mutants such that the cho1∆/cho1∆ mutant appeared
most defective, psd1∆/psd1∆ psd2∆/psd2∆ was somewhat less defective, and the
psd1∆/psd1∆ mutant was the least defective, but was slightly more perturbed than the
wild-type strain (Fig 3-7B).
Defects in PE and PS biosynthesis result in cell wall defects
The cho1∆/cho1∆, psd1∆/psd1∆, and psd1∆/psd1∆ psd2∆/psd2∆ mutants all
exhibit growth defects compared to the wild-type strain (Figs 3-5 and 3-8). A PS
synthase mutant in Schizosaccharomyes pombe (pps1∆) has been shown to exhibit slow
growth due to cell wall defects (112). The C. albicans phospholipid biosynthetic mutants
were therefore tested to determine if they too exhibited slow growth due to cell wall
defects by growing them on plates containing osmotic stabilizers. All three mutants grew
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like wild-type on plates containing 1M sorbitol, 0.8M NaCl, or 0.1M CaCl2 (Fig 3-8A).
This indicated that these mutants all exhibited some form of cell wall defect. The coldsensitive growth described above (Fig 3-7A) was not rescued by growth in osmoremedial
media (Y. -L. Chen and T. B. Reynolds, data not shown). In addition, osmotic
stabilization did not rescue the auxotrophic defects reported above (data not shown).
The nature of the cell wall defect was further explored by examining different
insults that perturb the cell wall. The cho1∆/cho1∆ mutant and the psd1∆/psd1∆
psd2∆/psd2∆ double mutant both showed a strong sensitivity to 0.05% SDS, which is
thought to measure cell wall permeability (167). The cho1∆/cho1∆ mutant was more
defective in this assay than the psd1∆/psd1∆ psd2∆/psd2∆ mutant. The psd1∆/psd1∆
mutant did not appear to be more sensitive than wild-type on YPD plates containing
0.05% SDS (Fig 3-8B). In contrast, all three phospholipid biosynthetic mutants exhibited
increased resistance to caffeine compared to the wild-type strain (Fig 3-8C). None of the
mutants were affected by calcofluor white in the media (data not shown). Addition of the
chitin synthase inhibitor nikkomycin Z appeared to cause a very slight defect in growth of
the cho1∆/cho1∆ mutant, although it was hard to measure as the mutant exhibits a growth
defect already compared to the wild-type, and the wild-type strain is also slightly
inhibited by nikkomycin Z (see Appendix). The cho1∆/cho1∆ mutant also exhibited a
defect visualized by transmission electron microscopy (TEM) that was not seen in the
psd1∆/psd1∆ psd2∆/psd2∆ double mutant or the psd1∆/psd1∆ single mutant. TEM
revealed that the cho1∆/cho1∆ mutant had a higher percentage of cells that exhibited an
altered distance between the plasma membrane and cell wall (Fig 3-8D), suggesting a
defective plasma membrane or cell wall.
The cho1∆/cho1∆ and psd1∆/psd1∆ psd2∆/psd2∆ mutants exhibit defects in
filamentous growth
Filamentous growth is a well known virulence factor in C. albicans, and mutants
that show severe defects in this phenotype also often exhibit altered virulence. Mutants in
mitochondrial respiration enzymes such as Ndh51p have shown defects in filamentous
growth (114). Therefore, filamentous growth was examined in the cho1∆/cho1∆ and
psd1∆/psd1∆ psd2∆/psd2∆ mutants. Strains were streaked onto plates and grown in
conditions known to promote filamentous growth including medium 199 at pH 7.0
(M199-7), Spider medium, and YPD+10% serum. In comparison to the wild-type, the
cho1∆/cho1∆ and psd1∆/psd1∆ psd2∆/psd2∆ mutants were poorly filamentous (Fig 39A). However, if the media were osmotically stabilized by the addition of 1M sorbitol,
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then the cho1∆/cho1∆ mutant exhibited greater filamentous growth (Fig 3-9B). It was
still less filamentous than wild-type on M199-7, but it was more filamentous than wildtype on spider and YPD+10% serum media. Filamentous growth in the psd1∆/psd1∆
psd2∆/psd2∆ mutant, in contrast, was not rescued by osmotic stabilization (Fig 3-9B).
At very early time points, the cho1∆/cho1∆ mutant was actually hyperfilamentous
on YPD+10% serum medium compared to wild-type, even without osmotic stabilization
(data not shown), but at later time points the colonies appeared less filamentous (Fig 39A). The cho1∆/cho1∆ mutant also formed hyper-wrinkled colonies on YPD containing
medium, both ± serum (data not shown). Neither of these effects were observed in the
psd1∆/psd1∆ psd2∆/psd2∆ mutant (data not shown).
The behavior of the mutants was also examined in liquid serum. In 100% bovine
calf serum, it was found that the cho1∆/cho1∆ mutant exhibited slower germ tube
formation than the wild-type, and after a few hours growth was arrested altogether (Fig 39C). The addition of extra Etn rescued filamentous growth in the cho1∆/cho1∆ mutant,
but extra Cho had no effect (data not shown). The psd1∆/psd1∆ and psd1∆/psd1∆
psd2∆/psd2∆ mutants, in contrast, exhibited nearly wild-type levels of filamentous
growth (Fig 3-9C).
DISCUSSIONS
The cho1∆/cho1∆ mutant in C. albicans is clearly avirulent in a mouse model of
systemic candidiasis (Fig 3-3), and cannot even cause disease in a mouse
immunocompromised with cyclophosphamide when infected with 100-fold more
blastospores than the wild-type strain (Fig S3-1). Examination of the mouse kidneys
quantitatively (Fig 3-3C, S3-1) and qualitatively (Figs 3-4 and S3-1) reveal that the
cho1∆/cho1∆ mutant is eventually completely cleared from mice and causes no apparent
tissue damage. The loss of PS synthesis plays a very important role in the loss of
virulence, but the downstream loss of de novo PE synthesis (Fig 3-1) also causes a loss in
virulence. This conclusion is based on the fact that a psd1∆/psd1∆ psd2∆/psd2∆ double
mutant is extremely attenuated for virulence (Fig 3-3B). This double mutant lacks de
novo PE biosynthesis, like the cho1∆/cho1∆ mutant, and has a very similar drop in total
cellular PE (Table 3-1). However, unlike cho1∆/cho1∆, the double mutant does not lack
PS.
Based on our results, we propose that the cho1∆/cho1∆ and psd1∆/psd1∆
psd2∆/psd2∆ mutants share a number of defects in cell wall integrity, mitochondrial
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function, and filamentous growth that contribute to their loss of virulence. However, the
cho1∆/cho1∆ mutant has an additional phenotype, not shared with the psd1∆/psd1∆
psd2∆/psd2∆ mutant, that makes it completely avirulent. This phenotype is its severe
growth defect in the presence of Cho as the sole exogenous source for the Kennedy
pathway (Fig 3-1).
We could not find the serum level of choline or ethanolamine in mice, but rat
serum is estimated to contain ~10 µM Cho, and is higher in some other organisms (6,
185) . We found that the cho1∆/cho1∆ mutant had a very slow doubling time of ~36
hours in media supplemented with 10 µM Cho (Table 3-2). Supplementing the media
with 1 mM Cho (100 x increase) did not increase the growth rate in the early time points
and had a modest effect only after several days (data not shown). Rat serum also contains
an estimated 30 µM Etn (87), however, C. albicans cho1∆/cho1∆ and psd1∆/psd1∆
psd2∆/psd2∆ mutants require a minimum of ~1 mM Etn to fulfill their auxotrophic
requirements, so the level of Etn in the serum is inadequate to support growth of the
cho1∆/cho1∆ mutant. This is reflected by the inability of the cho1∆/cho1∆ mutant to
progress beyond initial germ tube formation in 100% serum unless supplemented with 1
mM Etn (Fig 3-9C), and the inability to appreciably grow in liquid or solid media
supplemented with 30 µM Etn (data not shown). We propose that the cho1∆/cho1∆
mutant is extremely avirulent because it is unable to grow in the host environment due to
insufficient Etn and Cho levels.
The behavior of the C. albicans cho1∆/cho1∆ mutant in Etn vs Cho supplemented
glucose media is very different from the S. cerevisiae Sccho1∆ mutant when it is grown
on glucose media containing Etn or Cho, and is more akin to the Sccho1∆ mutant grown
on a non-fermentable carbon source supplemented with Etn or Cho (13). On nonfermentable carbon sources, such as lactate, the Sccho1∆ mutant is also only able to grow
on Etn. This is believed to be caused by the increased need for mitochondrial activity,
which is an organelle rich in PE. The DPL1 salvage pathway is not able to efficiently
supply Etn for the increased demand for mitochondrial activity. In fact, overexpression of
DPL1 rescues growth of Sccho1∆ mutants on non-fermentable carbon sources (13).
Based on the work from S. cerevisiae, it was expected that the lack of
responsiveness to Cho in the C. albicans cho1∆/cho1∆ mutant was due to the lack of de
novo PE formation and poor mitochondrial activity. If this were the case, then the
psd1∆/psd1∆ psd2∆/psd2∆ mutant should share this phenotype as it has a similar loss of
de novo PE synthesis (Table 3-1, Fig 3-1). However, this is clearly not the case in C.
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albicans (Fig 3-5). In fact, in this regard, C. albicans even differs from the PS synthase
mutant pps1∆ in S. pombe, another petite negative yeast. The pps1∆ mutant is also an Etn
auxotroph that cannot be supported by Cho even on fermentable carbon sources (112).
However, further work with a mutant lacking all three S. pombe PS decarboxylase genes
(psd1-3∆) has revealed that a lack of PE was the cause of the inability to respond to Cho
(103). Thus, inability to respond to Cho due to a loss of PS in particular is specific to C.
albicans. The reason for this defect is unknown, but several possibilities present
themselves. 1) In the psd1∆/psd1∆ psd2∆/psd2∆ mutant there is a buildup of PS. Perhaps,
PS can compensate for the lack of PE in the mitochondria. PS decarboxylase mutants in S.
pombe and S. cerevisiae also experience a buildup of PS (13, 112). So if this explanation
is correct, C. albicans is unusual. 2) The DPL1 pathway in C. albicans may be
compromised by a lack of PS, and this does not allow it to supply sufficient PE even on a
fermentable carbon source. 3) PS or PE is required for the function of several transporters
in S. cerevisiae (124, 131, 132, 146), and it is possible that the transporter for Cho in C.
albicans is inhibited by a loss of PS in the membrane. This has not been observed for the
Cho transporter, Hnm1p (96), in S. cerevisiae, but may be the case for the transporter in C.
albicans. If this is the case, then cells growing on Cho alone would not be able to make
sufficient PC via the Kennedy pathway to grow efficiently (Fig 3-1). Whatever the reason
for the inability of Cho to supplement growth of the cho1∆/cho1∆ mutant in the presence
of Cho alone, we believe that is an important contributor to its loss of virulence.
Loss of de novo PE biosynthesis also contributes to a loss of virulence
The psd1∆/psd1∆ psd2∆/psd2∆ mutant is very attenuated for virulence. It suffers
a growth defect compared to wild-type, but in comparison to the fully virulent
psd1∆/psd1∆ mutant, its growth is not seriously diminished (Fig 3-5, Table 3-2). This
result suggests to us that the psd1∆/psd1∆ psd2∆/psd2∆ mutant is defective in virulence
for reasons other than a slightly diminished growth rate. This mutant, like the
cho1∆/cho1∆ mutant exhibits defects in cell wall biosynthesis, mitochondrial function,
and hyphal growth. All of these factors might contribute to a loss of virulence and
inability to grow in the host.
Three of the phospholipid mutants in this analysis, psd1∆/psd1∆, cho1∆/cho1∆,
and psd1∆/psd1∆ psd2∆/psd2∆, all exhibited some level of cell wall defects including
osmoremedial growth and resistance to caffeine (Fig 3-8). However, only the two
virulence-defective mutants, cho1∆/cho1∆ and psd1∆/psd1∆ psd2∆/psd2∆, exhibited a
strong sensitivity to SDS. SDS sensitivity can be interpreted to indicate an increased
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permeability of the cell wall (167). The cho1∆/cho1∆ mutant has a stronger defect than
the psd1∆/psd1∆ psd2∆/psd2∆ mutant in this regard, and also exhibits an increased
distance between the cell wall and plasma membrane in the electron micrographs that is
not seen in the psd1∆/psd1∆ psd2∆/psd2∆ mutant (Fig 3-8D). The reason for this may be
due to cell wall or plasma membrane defects, but is not known.
Both mutants suffer from a defect in de novo PE biosynthesis, which clearly
impacts the cell wall, but loss of PS itself has an impact on this phenotype. The loss of PE
may affect the cell wall by impacting glycosylphosphatidylinositol (GPI) anchored
protein maturation as has been seen for the Scpsd1∆ Scpsd2∆ mutant in S. cerevisiae. In
the Scpsd1∆ Scpsd2∆ mutant loss of de novo PE biosynthesis leads to poor maturation of
ScGas1p even in the presence of exogenous Etn in the media. An attempt was made to
compare the maturation of GPI-anchored proteins in C. albicans cho1∆/cho1∆ and wildtype strains by Western blotting using an antibody specific to ScGas1p that has been
shown to cross-react with similar C. albicans cell wall proteins. However, the results
were inconclusive (data not shown), and we do not know if GPI-anchor synthesis is
impacted in C. albicans in a similar manner as in S. cerevisiae. If so, then this may help
to explain the cell wall defects seen in the C. albicans psd1∆/psd1∆ psd2∆/psd2∆ mutant.
Alternatively, PE biosynthesis defects may impact virulence by affecting the
mitochondria.
Three of the phospholipid biosynthetic mutants, psd1∆/psd1∆,
cho1∆/cho1∆ and psd1∆/psd1∆ psd2∆/psd2∆, all exhibited resistance to paraquat on
plates (Fig 3-6A) suggesting that they have defects that affect respiration. The mutants
also exhibited very similar resistances to paraquat quantitatively, expect for the
psd1∆/psd1∆ psd2∆/psd2∆ mutant, but this may be due to its growth defect in nonosmoremedial media (Fig 3-6B). The paraquat resistance could be due to uncoupling of
oxidative phosphorylation, as an undefined C. albicans mutant that is uncoupled for
oxidative phosphorylation was also resistant to paraquat (26).
There was not an obvious difference between the virulent and non-virulent
mutants by the paraquat resistance assay, however the trypan blue/eosin Y indicator plate
assay revealed that the less virulent cho1∆/cho1∆ and psd1∆/psd1∆ psd2∆/psd2∆ mutants
gave a much stronger phenotype than the psd1∆/psd1∆ mutant (Fig 3-7B). The basis for
this assay is not understood, so the particular mitochondrial dysfunction that appears to
be worse in the cho1∆/cho1∆ and psd1∆/psd1∆ psd2∆/psd2∆ mutants compared to the
psd1∆/psd1∆ mutant is not known.
The cold-sensitive growth assay suggests that the cho1∆/cho1∆ mutant has a
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greater defect in mitochondrial genome stability. S. cerevisiae Sccho1∆ mutants show a
cold-sensitive increase in petite mutant formation. The psd1∆/psd1∆, cho1∆/cho1∆ and
psd1∆/psd1∆ psd2∆/psd2∆ mutants all showed a cold-sensitive growth defect, but
cho1∆/cho1∆ and psd1∆/psd1∆ psd2∆/psd2∆ mutants showed a stronger defect than the
psd1∆/psd1∆ mutant (Fig 3-7A). PE has been shown to be important for maintenance of
the mitochondrial genome, and these mutants’ phenotype may reflect a general instability
in mitochondrial proteins.
The defect observed in the mitochondria correlates with defects in the cell wall
and it is possible that these phenotypes are connected. The function of PE in maintaining
mitochondrial function overlaps with that of another mitochondrial lipid called
cardiolipin (CL) (56). Mutants that lack CL due to a defect in the Pgs1p enzyme in S.
cerevisiae have been shown to have cell wall defects due to dampened cell wall integrity
MAP kinase (CWI-MAPK) signaling (188, 189). It is possible that the PE deficiencies
caused by the cho1∆/cho1∆ and psd1∆/psd1∆ psd2∆/psd2∆ mutants lead to defects in
CWI-MAPK signaling.
The cho1∆/cho1∆ mutant is more defective for cell wall biosynthesis and
mitochondrial function than the psd1∆/psd1∆ psd2∆/psd2∆ mutant. The reason for the
increasing cell wall defect in the cho1∆/cho1∆ mutant may be related to the function of
PS in signal transduction. PS has been shown to stimulate ScPkc1p activity through
ScRom2p in S. cerevisiae (79). ScPkc1p is at the head of the CWI-MAPK cascade and
influences a number of aspects of cell wall biosynthesis (93). The loss of PS in C.
albicans may hamper Pkc1p activity and cell wall biosynthesis in this yeast. In addition,
PS has been shown to affect calcineurin activity as well (140). Calcineurin influences the
cell wall in bakers’ yeast and C. albicans (52, 181). Addition of 100mM CaCl2 to the
phospholipid mutants osmostabilizes their growth (Fig 3-8A), but addition of the
calcineurin inhibitors cyclosporine A or FK506 (66) slightly inhibits the osmoremediated
growth of the cho1∆/cho1∆ mutant (Fig S3-3), suggesting that PS is required for full
calcineurin activity in C. albicans.
The S. pombe pps1∆ PS synthase mutant also shows cell wall defects, however its
defects are exclusively due to the loss of PS, as a mutant lacking all three PS
decarboxylase genes (Sppsd1-3∆) does not exhibit similar cell wall defects as a pps1∆
mutant (103). In addition, the nature of the cell wall defects may differ as well. The C.
albicans mutants are not sensitive to calcofluor white and show only a very slight
sensitivity to the chitin synthase inhibitor Nikkomycin Z (data not shown). The pps1∆
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mutant is very sensitive to calcofluour white which is associated with binding to chitin
(112). Thus, the basic defects in the cell wall may be quite different in these two yeasts.
The cell wall defects in the psd1∆/psd1∆ psd2∆/psd2∆ mutant may help to
explain the defects in virulence as a number of cell wall mutants have been found that are
reduced in virulence (7, 110, 115, 119, 129, 135). One explanation for the reduced
virulence in some cell wall mutants is increased “unmasking” of ß1,3-glucan, and greater
immune response from the host (177, 178). This may be the case for the psd1∆/psd1∆
psd2∆/psd2∆ mutant, but this remains to be tested.
An interesting contrast to the strong virulence defect of the psd1∆/psd1∆
psd2∆/psd2∆ mutant is the psd1∆/psd1∆ mutant. In S. cerevisiae, the ScPsd1p enzyme is
localized to the mitochondria and produces 90% of the de novo synthesized PE in the cell.
The C. albicans Psd1p enzyme is likely similar since it is much more defective for
growth in the absence of Etn supplementation. In fact, as in S. cerevisiae, the Kennedy
pathway does not seem to be able to fully compensate in C. albicans in the absence of
Psd1p or both enzymes (13). The psd1∆/psd1∆ mutant is fully virulent even though it
does have cell wall and mitochondrial defects, although milder than the double mutant.
Surprisingly, the psd1∆/psd1∆ mutant actually colonized the kidneys to a greater extent
than the wild-type. The reason for this is not known, but it bears some resemblance to an
undefined C. albicans oxidative phosphorylation decoupling mutant. This mutant also
colonized the kidneys efficiently, but it was avirulent. This mutant was suggested by the
authors to carry multiple undefined mutations, so its avirulence and heavy colonization of
the kidneys may be unlinked (26). Thus, it is possible that the psd1∆/psd1∆ mutation’s
mitochondrial defect may help lead to better immune evasion and colonizing of the
kidneys. However, if this is the case, then even greater defects related to PE depletion (i.e.
psd1∆/psd1∆ psd2∆/psd2∆ mutant) lead to a loss of virulence and colonization. These
questions all remain to be resolved.
Filamentous growth in the absence of PE and PS
The cho1∆/cho1∆ and psd1∆/psd1∆ psd2∆/psd2∆ mutants exhibited defects in
filamentous growth in response to several different environmental stimuli such as pH,
glucose starvation, and serum (Fig 3-9). Filamentous growth has been associated with
virulence in C. albicans, and this could be a contributor to the avirulence of these strains
as well. The cho1∆/cho1∆ mutant was arrested in germ tube formation in serum (Fig 39C), but this is likely related to its growth defect in medium supplemented with Cho (Fig
3-5), as addition of extra Cho did not improve its growth, but 1 mM Etn did allow a
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recovery of filamentous growth (data not shown). The psd1∆/psd1∆ psd2∆/psd2∆ mutant
did not exhibit this defect in 100% serum (Fig 3-9C). It is of note that it has been shown
that disruption of the mitochondrial electron transport chain NADH dehydrogenase
complex I gene NDH51 leads to defects filamentous growth in basal salts medium (114).
Thus, the filamentous growth defects in the phospholipid mutants may be related to a loss
of mitochondrial capacity. Interestingly, the addition of 1 M sorbitol allowed a
hyperfilamentous growth in the cho1∆/cho1∆ mutant, but not the psd1∆/psd1∆
psd2∆/psd2∆ mutant (Fig 3-9). The reason for this recovery in the one mutant, but not the
other is not clear.
Conclusions
The phospholipid biosynthetic mutants described in this work make it clear that
loss of PS and de novo PE synthesis cause virulence defects. The pleiotropic nature of the
mutants makes it difficult to determine precisely why the mutants are less virulent, but we
believe the evidence supports the hypothesis that the loss PS leads to avirulence due to
extremely poor growth without Etn. The loss of PE may lead to a loss of virulence more
because of cell wall, mitochondrial, and/or filamentous growth defects. We suspect that
all of these defects are related to mitochondrial dysfunction, but this remains to be
determined.
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APPENDIX C: TABLES AND FIGURES

Table 3- 1. Phospholipid composition of wild type and phospholipid mutants in C.
albicans*
Strain
WT

Phospholipid composition (% of total)
PE
PI
PC
Others
14.5 ± 0.8
13.6 ± 0.9 53.6 ± 1.0 12.2 ± 1.7

PS
6.1 ± 0.8
a,b,c

cho1Δ/cho1Δ
cho1Δ/cho1Δ::CHO1
psd1Δ/psd1Δ
psd1Δ/psd1Δ::PSD1
psd1Δ/psd1Δ
psd2Δ/psd2Δ

d,e,f,g

h,i

a

d

0.2 ± 0.2
2.8 ± 0.0 b
8.0 ± 2.0
5.5 ± 0.2

8.7 ± 1.5
12.5 ± 0.3 e
11.1 ± 0.7 f
13.8 ± 0.5

11.2 ± 1.0 c

8.0 ± 1.1 g

15.6 ± 1.8
15.3 ± 1.0
14.4 ± 1.5
13.0 ± 0.8

61.0 ± 3.4 h
56.3 ± 0.9 i
55.2 ± 2.0
56.1 ± 1.6

14.5 ± 0.5
13.2 ± 0.5
11.3 ± 1.4
11.5 ± 0.6

14.0 ± 4.8 56.4 ± 8.0 10.4 ± 1.2

*Cultures were grown to uniform labeling in YPD medium containing 5 µCi/ml of [32P]
phosphoric acid. Lipids were extracted and analyzed as described in Material and
Methods. Data represent the mean ± standard deviation of one independent experiment
and one duplicate experiment. The P values indicated by superscripted lower case were a
(0.0003); b (0.002); c (0.003); d (0.004); e (0.02); f (0.005); g (0.001); h (0.02); i (0.02).
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Table 3- 2. Doubling times of wild type and phospholipid mutants
in Etn and Cho supplemented minimal media
Strain
Wild-type
cho1∆/cho1∆
psd1∆/psd1∆
psd1∆/psd1∆ psd2∆/psd2∆

Doubling time (hours)
Etn (1mM)
Cho (10µM)
1.6
1.5
3.3
36.0
2.0
2.0
2.3
2.2
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Table S3- 1. C. albicans strains
Strain
SC5314
(wild-type)
YLC132
YLC137
YLC142
YLC334
YLC337
YLC344
YLC335
YLC339
YLC345a
YLC240
YLC247
YLC254
YLC280
YLC294
YLC243
YLC250
YLC257
YLC271
YLC290
YLC299
YLC300
YLC331b
YLC373
YLC375

Parent

Genotype

Clinical isolate

Prototrophic wild type

SC5314
YLC132
YLC137
YLC137
YLC334
YLC337
YLC137
YLC335
YLC339
SC5314
YLC240
YLC247
YLC254
YLC280
YLC250
YLC243
YLC250
YLC257
YLC271
YLC271
YLC299
YLC300
YLC300
YLC373

cho1Δ::NAT1-FLP/CHO1
cho1Δ/CHO1
cho1Δ/cho1Δ::NAT1-FLP
cho1Δ/cho1Δ::SAT1-FLP
cho1Δ/cho1Δ
cho1Δ/cho1Δ::CHO1-SAT1
cho1Δ/cho1Δ::SAT1-FLP
cho1Δ/cho1Δ
cho1Δ/cho1Δ::CHO1-SAT1
psd1Δ::SAT1-FLP/PSD1
psd1Δ/PSD1
psd1Δ/psd1Δ::SAT1-FLP
psd1Δ/psd1Δ
psd1Δ/psd1Δ::PSD1-SAT1
psd2Δ::SAT1-FLP/PSD2
psd2Δ/PSD2
psd2Δ/psd2Δ::SAT1-FLP
psd2Δ/psd2Δ
psd2Δ/psd2Δ::PSD2-SAT1
psd2Δ/psd2Δ psd1Δ::SAT1-FLP/PSD1
psd2Δ/psd2Δ psd1Δ/PSD1
psd2Δ/psd2Δ psd1Δ/SAT1-PMET3-PSD1
psd2Δ/psd2Δ psd1Δ/psd1Δ::SAT1-FLP
psd2Δ/psd2Δ psd1Δ/psd1Δ

Source of reference

a

another separately derived cho1Δ/cho1Δ::CHO1 reintegrant strain.

b

conditional construct, second allele of PSD1 was controlled by MET3 promoter.

(55)
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
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Table S3- 2. Plasmids
Plasmids

Characteristics

pJK863
pSFS2A
pYLC130
pYLC326
pYLC341
pYLC231
pYLC286
pYLC234
pYLC288
pYLC314
pYLC324

CaNAT1-FLP cassette carrying nourseothricin resistance gene
SAT1 flipper carrying nourseothricin resistance gene
pJK863 flanked 5’ and 3’ CHO1NCR for CHO1 1st allele knock out
pSFS2A flanked 5’ and 3’ CHO1NCR for CHO1 2nd allele knock out
CHO1 reconstitution construct
pSFS2A flanked 5’ and 3’ PSD1NCR for PSD1 gene knock out
PSD1 reconstitution construct
pSFS2A flanked 5’ and 3’ PSD2NCR for PSD2 gene knock out
PSD2 reconstitution construct
SAT1 marked CaMET3 promoter construct
PSD1 conditional construct controlled by CaMET3 promoter

Source
of
reference
(154)
(143)
This study
This study
This study
This study
This study
This study
This study
This study
This study

78

Table S3- 3. PCR primers
Primer
JCO43
JCO44
JCO45
JCO46
TRO369
JCO96
JCO99
JCO169
JCO141
JCO142
JCO143
JCO144
JCO145
JCO157
JCO146
JCO147
JCO148
JCO149
JCO150
JCO158
JCO165
JCO166
JCO167
JCO168

Use
Disrupt CHO1
Disrupt CHO1
Disrupt CHO1
Disrupt CHO1
Confirm cho1Δ
Confirm cho1Δ, psd1Δ, psd2Δ
Confirm cho1Δ
Restore CHO1
Disrupt PSD1
Disrupt PSD1
Disrupt PSD1
Disrupt PSD1
Confirm psd1Δ
Restore PSD1
Disrupt PSD2
Disrupt PSD2
Disrupt PSD2
Disrupt PSD2
Confirm psd2Δ
Restore PSD2
PSD1 conditional construct
PSD1 conditional construct
PSD1 conditional construct
PSD1 conditional construct

Sequence (5’  3’)
AAAAAAGGTACCCCCCCCACTGAACTTTAACCAA
AAAAAAGGGCCCGAAAAGTGGAAGAAGAGCTGA
AAAAAACCGCGGTTTTGGTATTATCAGACGCTG
AAAAAAGAGCTCTGCTGTGAAGAGAGCAAATG
GCACGTCAAGACTGTCAAGG
TGAAGGGGGAGATTTTCACT
AGATCATTCAAGCTACCCAG
AAAAAAGCTTTCTCTATGGTTTAGGAATT
AAAAAAGGGCCCTAAAGCAGCGTGGTATCGTGA
AAAAAACTCGAGCAGTCAAACAAAGGAGTAACG
AAAAAACCGCGGAGGAAGCTCAGCGTAATGGTT
AAAAAAGAGCTCCAGTTGCAGATCTTGGTGTTG
TTCAACTTGTTGGTGACCCA
AAAAAAGATATCCCTCTATACGAACCCACCTAA
AAAAAAGGGCCCGAGTTGTAGCAAAAGTTACCG
AAAAAACTCGAGTGCTGGGTTGAGTTGAATTCT
AAAAAACCGCGGGTCGTACATTAAGCAAATGAA
AAAAAAGAGCTCCCGATTACTTTCCTCATCGT
AGCGGGGAATCAAGTTACAA
AAAAAAGATATCACTTTAATCTTCACTTTTGA
AAAGAATTCCGTCAAAACTAGAGAATAATAAAG
AAAGAATTCGTTTTCTGGGGAGGGTATTT
AAACCGCGGATGCCACTCAAACCTATTTCG
AAAGAGCTCCTATACGAACCCACCTAATGA
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Fig 3- 1. The aminophospholipid biosynthetic pathways of both yeast and humans consist
of two alternative pathways:
The de novo pathway and the Kennedy pathway, but there are significant differences in
the de novo pathways of mammals and fungi. The Kennedy pathways of the two
organisms are similar in structure, but the level to each is used to generate particular
phospholipids is indicated by the thickness of the arrows. Dark bold arrow are used the
most, dotted arrows the least, and thin solid arrows at intermediate levels. The de novo
pathways differ between mammals and yeast. The yeast makes PS from CDP-DAG via
the PS synthase (Cho1p) while mammals use Pss1 or Pss2 to make PS from PC or PE,
respectively. Yeast carries two decarboxylases which convert PS to PE while mammals
only carry one (PSD). Yeast convert PE to PC via three methylation reactions that are
performed by two different sequential methylase enzymes whereas mammals only have
one methylase (PEMT) that performs all three reactions. Etn: ethanolamine, Cho: choline,
PS: phosphatidylserine, PE: phosphatidylethanolamine, PC: phosphatidylcholine, CDPDAG:
cytidyldiphosphate
diacylglycerol,
DAG:
diacylglycerol,
PMME:
phosphatidylmonomethylethanolamine, PDME: phosphatidyldimethylethanolamine, EtnP: phosphoethanolamine, Cho-P: phosphocholine, Etn-CDP: ethanolaminecytididyldiphosphate, Cho-CDP: cholinecytidyldiphosphate, DHS: dihydrosphingosine.
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Fig 3- 2. CHO1 is required for phosphatidylserine synthesis in C. albicans.
(A) Structure of the CHO1 disruption construct. Approximately 500 base pairs of noncoding DNA flanking the 5’ and 3’ ends of the CHO1 gene (5’-and 3’-CHO1NCR,
respectively) were cloned onto either flank of the CaNAT1-FLP construct or SAT1 flipper
(143, 154). The SAT1 flipper regions are in parentheses. The thick dark arrows represent
the FRT sites of the FLP recombinase. The ball and stick represents the ACT1 terminator
(ACT1t) and the thinner arrow on a raised line represents the SAP2 promoter (PSAP2,
CaNAT1-FLP) or MAL2 promoter (PMAL2, SAT1 flipper). (B) The CHO1-SAT1 construct
used to reintegrate CHO1 into the cho1∆/cho1∆ mutant. (C) Southern blotting was used
to confirm the CHO1 disruptions. (D) Separation of phospholipids from wild type and
mutant strains. The four major phospholipids were examined in the wild-type and mutant
strains. Positions of the different phospholipid spots were determined by comparing them
with the migration of phospholipid standards, which are marked to the side of
autoradiogram. The identity of the PS band from the wild type has also been confirmed
by mass spectrometry (see text). (E) Five-fold spot dilution assays depicting the
sensitivity and resistance of the wild type and cho1Δ/cho1Δ mutants to papuamide B. The
strains were grown on YPD plates with or without papuamide B for 24h at 37°C.
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Fig 3- 3. The cho1∆/cho1∆ and psd1∆/psd1∆ psd2∆/psd2∆ double mutants are
compromised for virulence.
The survival of mice following intravenous challenge with 106 C. albicans blastospores
was monitored. The number of mice used in a specific strain is indicated in parentheses.
(A) Mice injected with cho1∆/cho1∆ mutants exhibited avirulence (P<0.0001 as
compared with wild type). (B) Mice injected with psd1∆/psd1∆ psd2∆/psd2∆ double
mutants exhibited very attenuated virulence (P<0.0001 as compared with wild type). (C)
The fungal burden in the kidneys was quantified at day 5 after infection. The error bar
represents the mean ± standard deviation of three randomly selected mice infected with
specific strains.

83

Fig 3- 4. Histological sections of kidneys dissected from mice infected with specific
strains.
The mice were sacrificed at day 5 after infection. Gomori Methenamine Silver (GMS)
and Hematoxylin and Eosin (H&E) staining were used to observe C. albicans
colonization and tissue damage, respectively. Bar = 50μm.
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Fig 3- 5. The cho1∆/cho1∆ and psd1∆/psd1∆ psd2∆/psd2∆ mutants are ethanolamine
auxotrophs.
(A) The cells were streaked onto Etn/Cho free medium supplemented with Etn , Cho, or
neither, and grown for 2 days at 37°C. For the growth curves shown in B and C, logphase cells were diluted into Etn free medium plus 1mM Etn (B) or 10 µM Cho (C) at a
concentration of 0.1 OD600/ml. The growth curves were measured every two hours for 8
hr (right hand graphs) and then once daily for 14 days (left hand graphs). The error bars
represent mean ± standard deviation of a triplicate experiment. .
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Fig 3- 6. The phospholipid biosynthetic mutants are resistant to paraquat.
(A) The overnight cultures were five-fold diluted and spotted onto YPD plates with or
without 10mM paraquat. The plates were incubated for 24h at 37°C. (B) The number of
colonies of the wild type and phospholipid biosynthetic mutant strains that could grow on
medium containing various concentrations of paraquat (0-10mM) were counted for each
strain and plotted. The colonies were counted after plates had been incubated at 37°C for
1 to 2 days. The asterisk represents a P value of <0.02 when comparing mutant’s survival
percentage to that of the wild type. The error bar represents the mean ± standard error of
the mean of one independent and one duplicate experiment.
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Fig 3- 7. Defects in PE and PS biosynthesis result in cold sensitivity and mitochondrial
respiration defects.
(A) Five fold dilutions of overnight cultures were spotted onto YPD medium and grown
at various temperatures for the indicated amounts of time. (B) A trypan blue & eosin Y
indicator plate was used to test for mitochondrial dysfunction. The streaked cells were
grown for 44 h at 37°C.
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Fig 3- 8. Defects in PE and PS biosynthesis result in cell wall defects.
(A) The overnight culture cells were five-fold diluted, spotted onto YPD containing
osmotic stabilizers CaCl2, sorbitol, or NaCl, and grown for 24 h at 37°C. (B) & (C) The
overnight culture cells were five-fold diluted and spotted onto YPD plates containing
SDS or caffeine. (D) The overnight cultures cells were washed and diluted into YPD
liquid medium at 0.4 OD/ml and grown at 37°C for 3h before collecting the cells for
transmission electron microscopy observation. The cell wall thickness was quantitatively
measured and plotted. The asterisk represents P value < 0.0001 as compared with wildtype.
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Fig 3- 9. The cho1∆/cho1∆ and psd1∆/psd1∆ psd2∆/psd2∆ mutants exhibit filamentous
growth defects.
Strains were streaked onto plates without (A) and with (B) 1M sorbitol and grown at
37°C for appropriate time. (C) Overnight cultures grown at 37°C with shaking were
washed twice and diluted into 100% serum to a concentration of 0.01 OD/ml. Cells in
100% serum were transferred to polystyrene plastic well and incubate at 37°C for 4 hrs.
Pictures were taken under microscope at 600X magnification.
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Fig S3- 1. The cho1∆/cho1∆ and psd1∆/psd1∆ psd2∆/psd2∆ double mutants are
compromised for virulence in immunocompromised mice.
Mice that were immunocompromised with cyclophosphamide were injected with 106
blastospores of cho1/cho1Δ mutants, whereas mice injected with the wild type,
psd1∆/psd1∆, or psd1∆/psd1∆ psd2∆/psd2∆ double mutant strains received 104
blastospores. Thus, mice received 100-fold more cho1∆/cho1∆ blastopores than
blastospores from other strains. The survival of mice following intravenous challenge
was monitored twice a day. The number of mice used in a specific strain is indicated in
parantheses. (A) Mice injected with cho1∆/cho1∆ and psd1∆/psd1∆ psd2∆/psd2∆ double
mutants exhibited avirulence and attenuated virulence, respectively. However,
psd1∆/psd1∆ was as fully virulent as the wild-type. (B) The fungal burden in the kidneys
was quantified from mice sacrificed at day 4. The error bars represents the mean ±
standard deviation of three randomly selected mice infected with specific strains. (C) The
kidney appearance of infected mice at day 4 was examined. Bar=1cm.
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Fig S3- 2. Southern blotting confirmed the PSD1 and PSD2 disruptions.
The genomic DNAs were extracted from wild-type and mutants. (A) Twenty µg of DNA
from wild type and psd1Δ/psd1Δ strains were digested by XhoI, and probed using a DNA
fragment representing the 3’ noncoding region of the PSD1 gene. (B) Twenty µg of DNA
from wild type and psd2Δ/psd2Δ strains were digested by BamHI, and probed using a
DNA fragment representing the 3’ noncoding region of the PSD2 gene.
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Fig S3- 3. The cho1∆/cho1∆ cell wall defect appears to be in part due to perturbation of
calcineurin.
The overnight cultures were five-fold diluted, spotted onto YPD containing 100mM
CaCl2with or without calcineurin inhibitor CsA or FK506, and grown for 45 h at 37°C.
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ABSTRACT
The yeast Candida albicans is a very common cause of fungal infections in
humans and serves as a model organism to study fungal virulence. C. albicans is a
versatile pathogen that can cause life-threatening systemic infections in
immunocompromised patients as well as painful mucosal infections of the oral and
vaginal surfaces. Virulence factors exhibited by C. albicans include growth at 37°C,
dimorphism, and production of secreted hydrolases such as proteases, lipases, and
phospholipases. The pathways that regulate the transcription of secreted aspartyl protease
(SAP) virulence factors in C. albicans are beginning to be understood, but much remains
to be learned. Here we report the finding that the gene OPI1 affects the virulence of C.
albicans. Homozygous disruptants of OPI1 (opi1Δ/opi1Δ) exhibits a significant reduction
in virulence compared to wild-type in a rat model of vaginal infection. This phenotype is
similar to that reported for the sap2Δ/sap2Δ mutant and suggests that OPI1 may regulate
SAP2 during vaginal infections. Conversely, the opi1Δ/opi1Δ strain does not have a
substantial effect on virulence in a mouse model of systemic infection. Thus, OPI1
affects virulence in a host-site specific manner. The best characterized homologue of
OPI1 is the Saccharomyces cerevisiae gene ScOPI1, which encodes a negative regulator
of inositol biosynthesis that acts by repressing transcription of the inositol biosynthetic
gene INO1. We have found that in C. albicans, OPI1 does not play a role in the regulation
of INO1. Taken together, our results describe a novel regulatory protein is required for
establishing infection in rat vagina and illustrate that the regulation of inositol
biosynthesis in C. albicans and S. cerevisiae is different.
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INTRODUCTION
Candida albicans is a commensal organism that lives as benign resident of the
microflora of mammalian hosts. It can shift from a commensal to a pathogenic state in
response to environmental stimuli that trigger developmental programs that induce the
expression of virulence factors (65). Virulence factors exhibited by C. albicans include
growth at 37°C, dimorphism, and production of secreted hydrolases such as proteases,
lipases, and phospholipases. The pathways that regulate the transcription of secreted
aspartyl protease (SAP) virulence factors in C. albicans are beginning to be understood,
but much remains to be learned. SAPs are encoded by a gene family of 10 related genes
(SAP1 to SAP10) (123). Unlike SAP1 to SAP8, which encode secreted proteases, SAP9
and SAP10 encode GPI-anchored proteases, located at cell membrane or cell wall, and
both are required for virulence (1). Among this family of genes, Sap2p is the most wellstudied protease since it plays the major secreted protease during in vitro growth
conditions, and also plays a role in pathogenesis.
The knowledge of SAP2 regulation is limited. SAP2 is under the control of STP1
transcription factor and STP1’s upstream GATA transcription factors GLN3 and GAT1 (34,
111). The importance of SAP2 in pathogenesis has been discussed by several groups. For
instance, De Bernardis et al. demonstrated that SAP2 was the major virulence contributor
in the rat vaginitis model (38). Schaller et al. showed that SAP2 was required to cause
tissue damage in an in vitro model of vaginal candidiasis (149). In addition, Hube et al.
demonstrated that SAP2 was required for virulence in a the rodent model of systemic
infection (74). In contrast, Lermann and Morschhauser showed data contradictory to
Schaller et al, 2003 that SAP2 was not required to invade and damage in both oral and
vaginal reconstituted human epithelium (91). Thus, there is controversy about the role of
SAP2 in pathogenesis.
S. cerevisiae OPI1 (ScOPI1) is a negative regulator of inositol biosynthesis which
inhibits ScINO1’s transcriptional activator ScINO2 (174, 179). In addition, it plays a role
as a regulator of ScFLO11, an adhesion molecule, and is required for invasive growth and
mat formation in S. cerevisiae (144). Inositol-3-phosphate synthase, encoded by ScINO1,
catalyzes the conversion of glucose-6-phosphate to inositol-3-phosphate, which is then
dephosphorylated by INM1 or INM2 to form inositol (24). The structural gene encoding
ScINO1 has been demonstrated to be conserved between S. cerevisiae and C. albicans,
and shares similar function (25, 84). C. albicans and S. cerevisiae INO1 homologs are
similarly regulated in response to exogenously provided inositol (83). The ScOPI1
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orthologue in C. albicans (OPI1) can complement Scopi1Δ for INO1 regulation in S.
cerevisiae (68). We therefore hypothesized that OPI1 might function as an INO1 negative
regulator in C. albicans. However, a report from Hoppen et al. suggested that the
regulation of the INO1 expression in these two yeasts might not be conserved. The C.
albicans heterodimeric transcription factors INO2 and INO4 (related to ScINO2 and
ScINO4 from S. cerevisiae) did not regulate INO1, but instead activated ribosomal protein
genes such as RPL32 (71). The results indicated that inositol regulation might be
transcriptional rewired between these two related eukaryotic organisms. In fact,
Martchenko et al. has demonstrated that the GAL4 transcription factor homologs appear
rewired between these two organisms. In C. albicans the GAL4 homolog activated the
gluconeogenesis gene LAT1 instead of galactose metabolism genes such as GAL10, and
surprisingly GAL10 was activated by another transcription factor CPH1 (107). Therefore
it is very interesting to investigate if OPI1 shares similar inositol regulation as ScOPI1.
Here we report the finding that OPI1 does not regulate inositol biosynthetic gene
INO1 but affects the virulence of C. albicans. In addition, OPI1 affects morphogenesis at
30ºC, and establishing infection in a rat vaginitis model. These results illustrate that the
regulation of inositol biosynthesis in C. albicans and S. cerevisiae is different.
MATERIALS AND METHODS
Strains and growth media
C. albicans strains used in this study are shown in Table 4-1 (see all tables and
figures in the appendix C). Media used in this study include YPD (yeast extract-peptonedextrose, 1% yeast extract, 2% peptone, 2% glucose), defined medium 199 (M199,
Invitrogen, pH7.0 adjusted by 150mM HEPES), Spider (1% nutrient broth, 1% mannitol,
0.2% dipotassium phosphate, 1.35% agar), YPD containing 10% Bovine Fetal serum,
YCB-BSA-YE (1.17% yeast carbon base, 0.2% BSA, 0.1% yeast extract, pH 5.0). Unless
otherwise stated, agar plates were solidified with 2% agar (granulated, Fisher).
Strain construction
The C. albicans OPI1 gene (OPI1) was disrupted by using the CaNAT1-FLP
cassette (154). For the OPI1 disruption construct, the 379 basepair (bp) 5’ non-coding
region (NCR) of OPI1 was amplified with primers TRO522 and TRO526 (Table 4-3),
and cloned as a KpnI-ApaI digested 228bp fragment into pJK863 5’ of the CaNAT1-FLP
cassette (Fig 4-1A). The 448 bp 3’ NCR of OPI1 was amplified with primers TRO524
and TRO525 which introduced SacII and SacI sites, and was cloned into pJK863 3’ of the
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CaNAT1-FLP cassette (Fig 4-1A). This created the OPI1 knock out construct plasmid
pYLC36 (Table 4-2, Fig 4-1A), which was cut with KpnI and SacI to release the
disruption construct which was transformed into the wild type SC5314 strain by
electroporation as described previously (36, 143). The disruption construct was used to
sequentially disrupt both alleles of OPI1 as previously described (154). The OPI1
reconstitution construct was made by amplifying a 1.7 Kb fragment containing the OPI1
ORF and 5’ NCR from SC5314 genomic DNA using primers (JCO12 and JCO14) that
introduced KpnI and SalI sites. This fragment was ligated into the pRS316 vector along
with another 1.7 Kb fragment containing the NAT1-3’OPI1NCR amplified from plasmid
pYLC36 using primers JCO50 and TRO525 which introduced SalI and SacI sites. This
resulted in the OPI1 reconstitution plasmid pYLC37 (Table 4-2, Fig 4-1B). The 3.4 Kb
KpnI-SacI fragment from pYLC37 was transformed into the opi1∆/opi1∆ mutant (YLC88)
in order to create the reconstituted opi11∆/opi1∆::OPI1 strain (YLC117).
The SAP2 constitutively expression construct was made by cloning dominant
selectable marker NAT1 with primers JCO129 and JCO130 to NdeI-digested pAU34 (168)
and resulted in pYLC219. The SAP2 ORF was then cloned to XmaI-digested pYLC219
with primers JCO131 and JCO132, and resulted in pYLC221 which can constitutively
express SAP2 under the control of the ACT1 promoter. To transform this constitutive
construct to wild type and opi1∆/opi1∆ mutant, a PpuMI-digested linear plasmid
pYLC221 was used to integrate at URA3 site of Candida genome, and resulted in
OPI1/OPI1::pACT1::SAP2 (YLC223) and opi1∆/opi1∆:: pACT1::SAP2 (YLC226).
Northern blot analysis
Northern blotting for SAP2 and INO1 expression was performed as described
(144) with the following exceptions. Strains grown in YCB-BSA-YE at 37°C for 12 hrs
(for SAP2) and in liquid medium 199 (pH 7.0) at 37°C for 2 hrs (for INO1) were
collected for total RNA extraction by the hot phenol method (144). The PCR product
containing bps 17-571 of the SAP2 ORF (primers JCO35 and JCO36) and bps 76-581 of
the INO1 ORF (primers TRO562 and TRO563) were used as probes. Expression was
normalized against C. albicans ACT1 gene expression probed on the same membrane.
The ACT1 probe was generated with the primers JCO48 and JCO49.
Southern blot analysis
Hybridization conditions for the Southern blot analysis were similar to those for
Northern blot analysis, except that the Techne Hybrigene oven was set to 60°C for the
incubation step, and 42°C and 60°C for washing steps. The cells were grown in liquid
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YPD at 30°C overnight. The genomic DNA was extracted using the Winston-Hoffman
method (70) and 20µg of genomic DNA were subjected to Southern blotting. The
genomic DNA of opi1 mutants was cut by KpnI and SphI restriction enzymes. PCR
products containing the ~500bp 3’ NCR of OPI1 (primers TRO524 and TRO525) was
used as probes for Southern blot confirmation (Fig 4-1C).
Mouse infection studies
Five- to six-week-old male CD1 mice (18 to 20g) from Charles River
Laboratories were used in this study. Mice were housed at five per cage. For infection,
colonies from each C. albicans strain were inoculated into 20ml of YPD. Cultures were
grown overnight, washed twice with 25ml of sterile water, counted by hemacytometer,
and resuspended at 107 cells per ml in sterile water. The cells were then plated on YPD to
determine the viability. Mice were injected via the tail vein with 0.1ml of the cell
suspension (106 cells), and the course of infection was monitored for up to 14 days. At
least two independent infections were performed for each strain. Survival was monitored
twice daily, and moribund mice were euthanized. All experimental procedures were
carried out according to the NIH guidelines for the ethical treatment of animals.
The statistical analysis was done using Prism 4.0 software (GraphPad Software).
For the mouse model of systemic infection, Kaplan-Meier survival curves were compared
for significance using the Mantel-Haenszel log rank test. Statistical significance was set at
P < 0.05.
Rat vaginitis studies
The protocol of estrogen-dependent rat vaginal infection model adapted from De
Bernardis F. et al (38) was used throughout this study. Briefly, oophorectomized female
Wistar rats (80-100g; Charles River, Calco, Italy) were injected subcutaneously with
0.5mg of estradiol benzoate (Benzatrone; Samil, Rome). Six days after the first estradiol
treatment, the animals were inoculated intravaginally with 107 yeast cells of each C.
albicans strain tested in 0.1mL. The inoculum was dispensed into the vaginal cavity
through a syringe equipped with a multipurpose calibrated tip (Combitip; PBI, Milan,
Italy). The yeast cells had been previously grown in YPD broth at 28°C on a gyratory
shaker (200rpm), harvested by centrifugation (1500g), washed, counted in a
hemacytometer, and suspended to the required number in saline solution. At least two
independent experiments were done, and in each experiment, each candidal strain was
inoculated into at least 5 rats. Kinetics of C. albicans growth in and clearance from the
vaginal cavity was measured by cfu enumeration after culturing vaginal samples in CSA
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medium at 28°C for 48h. The samples were harvested by scraping the vaginal cavity of
each animal in indicated days with a calibrated, plastic loop (1μL) (Disponoic; PBI).
RESULTS
OPI1, unlike ScOPI1, does not regulate INO1 in C. albicans
Though C. albicans Opi1p has been demonstrated to repress INO1 expression in S.
cerevisiae (68), we show that it does not play a role in inositol regulation in C. albicans.
Both copies of the CaOPI1 gene were disrupted using the CaNAT1-FLP cassette as
described in Fig 4-1 and the materials and methods. The wild type and opi1Δ/opi1Δ
strains were both found to express similar amounts of INO1 mRNA in Medium 199, pH
7.0, which contains only ~ 10 µM inositol (Fig 4-2). INO1 mRNA expression was
repressed in the presence of 75μM inositol in both strains suggesting that inositol
biosynthesis is regulated by different transcription factors in C. albicans.
opi1Δ/opi1Δ mutant exhibits hyperfilamentous growth in three filament-inducing
media at 30ºC
From our previous work, we showed that ScOPI1 regulates mat formation,
invasive growth, and ScFLO11 expression (144). We therefore hypothesized that OPI1
would affect filamentous growth in C. albicans. Three filament-inducing media were
used to test our hypothesis. We found that the opi1Δ/opi1Δ exhibited hyperfilamentous
growth at 30°C on solid filament-inducing agar plates (Fig 4-3); however, these effects
were not seen at 37°C. These phenotypes were also not seen in those filament-inducing
liquid media at both 30°C and 37°C.
Since we found the OPI1 affected filamentous growth on filament-inducing solid
agar plates, we hypothesize that this gene might affect the expression of other hyphaespecific genes, such as HWP1 and ECE1. However, we found OPI1 is not involved in
regulating expression of those genes (data not shown).
OPI1 does not affect virulence in a mouse model of systemic infection
A gene involved in regulating C. albicans morphogenesis might play as a
virulence factor (180). We therefore used a mouse model of systemic infection to test the
roles of OPI1 in terms of virulence. However, we demonstrated that OPI1 did not
contribute to the virulence in this model since opi1Δ/opi1Δ exhibited a similar survival
curve as the wild type (Fig 4-4).
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OPI1 is involved in establishing infection in the rat vaginitis model
We then use different animal model to test the roles of OPI1 in terms of virulence.
We demonstrated that OPI1 was involved in establishing rat vaginitis. We injected 107
cells into the rat vaginal tract, and then recovered and count cells at specific days. The
opi1Δ/opi1Δ was very quickly cleared by the host compared to the wild type (Fig 4-5).
These results suggest that OPI1 plays a role in establishing infection in rat vaginal.
OPI1 affects rat vaginal establishment through regulating SAP2
In order to assess whether OPI1 affects rat vaginal establishment through
regulating SAP2, we performed an epistatis experiment in which SAP2 was constitutively
expresed in the opi1Δ/opi1Δ mutant under the control of the ACT1 promoter. The results
showed that opi1Δ/opi1Δ::pACT1::SAP2 mutant rescued rat vaginal establishment
similar to wild type establishment (Fig 4-6).
DISCUSSIONS
Our reports show that OPI1 affects virulence in the rat vaginitis model and may
affect SAP2 expression in vivo because opi1Δ/opi1Δ::pACT1::SAP2 mutant can restore
opi1Δ/opi1Δ mutant colonization. However, OPI1 did not regulate SAP2 in our in vitro
experiment (i.e. YCB-BSA-YE medium). Interestingly, OPI1 is not involved in a mouse
model of systemic infection, suggesting OPI1 exhibited a host-specific virulence.
The previous report has demonstrated that OPI1 may regulate inositol
biosynthesis and act as the negative regulator of INO1 (68). Our results show that OPI1
does not regulate inositol biosynthesis or INO1. This difference may be due to the fact
that in the previous report the C. albicans OPI1 was only studied when expressed
heterologously in S. cerevisiae. The fact that it could complement the Scopi1Δ mutant’s
defect in repressing ScINO1 (ICRE-regulated reporter gene) expression was taken as
evidence it did the same thing in C. albicans (68).
CaOpi1p may work in S. cerevisiae because it can interact with the ScIno2p and
ScIno4p heterodimer to repress ScINO1 expression. CaOPI1 did not regulate INO1 in C.
albicans indicating that different transcriptional regulators control INO1 in this pathogen.
We screened C. albicans transcription factor mutant library (provided by Aaron
Mitchell and Dominique Slangard) to isolate INO1 regulator. However, we did not find
any candidate in these mutant libraries. It will be interesting to identify what are the
transcriptional activators of INO1 in C. albicans.
OPI1 affects morphogenesis at 30ºC, but not at 37ºC (Fig 4-3). The opi1Δ/opi1Δ
103

mutant exhibited hyperfilamentous growth in three filament-inducing agar plates
including medium 199, spider, and 10% serum at 30ºC. The result indicated that OPI1
might be a temperature regulator of filamentous growth. Csank et al. demonstrated that C.
albicans CPP1, a tyrosine phosphatase, is required for repressing the yeast to hyphal
transition at 23ºC in contact with solid surfaces (32, 71). The cpp1Δ/cpp1Δ mutant
exhibited hyperfilamentous and invasive growth on spider and wide variety of rich and
defined solid media including Lee’s medium, YPD, YPM, and 10% serum at 23ºC, but
not at 37ºC. The germ tube formation of cpp1Δ/cpp1Δ mutant was not observed at liquid
culture at 37ºC, an effect similar to opi1Δ/opi1Δ mutant. In contrary to opi1Δ/opi1Δ, the
cpp1Δ/cpp1Δ mutant exhibited reduced virulence/pathogenecity in mouse systemic
infection and mouse mastitis model (32, 61). It is possible that Cpp1p and Opi1p may
interact in some way.
In the future, it will be tested if OPI1 regulates rat vaginitis through affecting
SAP2 expression in vivo using qRT-PCR to assay mRNA from collected rat vaginal fluid
infected with C. albicans wild-type and mutant strains. Taken together, our data
suggested that C. albicans has a transcriptionally rewired regulator OPI1 which does not
regulate inositol biosynthesis but affects morphogenesis, and virulence in rat vaginitis
model.
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APPENDIX D: TABLES AND FIGURES

Table 4- 1. C. albicans strains
Strain
SC5314
(wild-type)
YLC58
YLC85
YLC86
YLC88
YLC117
SAP2MS4A
YLC223
YLC226

Parent

Genotype

Clinical isolate

Prototrophic wild type

SC5314
YLC58
YLC85
YLC86
YLC88
SC5314
SC5314
YLC88

opi1Δ::NAT1-FLP/OPI1
opi1Δ/OPI1
opi1Δ/opi1Δ::NAT1-FLP
opi1Δ/opi1Δ
opi1Δ/opi1Δ::OPI1
sap2Δ/sap2Δ
OPI1/OPI1::PACT1::SAP2
opi1Δ/opi1Δ::PACT1::SAP2

Source of
reference
(55)
This study
This study
This study
This study
This study
(159)
This study
This study
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Table 4- 2. Plasmids
Plasmids
pJK863
pYLC36
pYLC37
pAU34
pYLC219
pYLC221

Characteristics
CaNAT1-FLP cassette carrying nourseothricin resistance gene
pJK863 flanked 5’ and 3’ OPI1NCR for OPI1 gene knock out
OPI1 reconstitution construct
Constitutively expression construct under the control of ACT1 promoter
pAU34 contained NAT1 selectable marker
pYLC219 contained SAP2 ORF for constitutive expression

Source of reference
(154)
This study
This study
(168)
This study
This study
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Table 4- 3. PCR primers
Primer
JCO522
JCO526
JCO524
JCO525
JCO12
JCO14
TRO369a
TRO532
JCO48
JCO49
JCO35
JCO36
TRO562
TRO563
JCO129
JCO130
JCO131
JCO132
JCO133
JCO134
JCO122

Use
Disrupt OPI1
Disrupt OPI1
Disrupt OPI1
Disrupt OPI1
Restore OPI1
Restore OPI1
Confirm OPI1 disruptions
Confirm OPI1 disruptions
ACT1 Northern blot probe
ACT1 Northern blot probe
SAP2 Northern blot probe
SAP2 Northern blot probe
INO1 Northern blot probe
INO1 Northern blot probe
SAP2 constitutive expression
SAP2 constitutive expression
SAP2 constitutive expression
SAP2 constitutive expression
SAP2 constitutive expression
SAP2 constitutive expression
SAP2 constitutive expression

Sequence (5’  3’)
AAAAAAGGGCCCTACACACACACACACTTACACACAT
AAAAAAGGGCCCCGGTTTCCCCCTTTTTATATA
AAAAAACCGCGGTGAGTGGTGGTTTCTTTTTGTT
AAAAAAGAGCTCCAAGTTGGACTACAAATGGTCAAG
GTGTGGTACCTATTTCCAAATTCA
AAAAGTCGACCTACTACACACTACCATCTA
GCACGTCAAGACTGTCAAGG
ACGGCATGCTAGGTATATACTGCT
CCAGCTTTCTACGTTTCC
CTGTAACCACGTTCAGAC
TTCATTGCTCTTGCTATTGCT
CACCGGCTTCATTGGTTTTA
GAAAACTCTGTTGTTGAAAAAGATG
TTGTTGGCACGTTCACTTTG
AAAAAACATATGCCCCGCGGGATATCAAGC
AAAAAACATATGTGGGTACCGAATTCGAGCT
AAAAAACCCGGGATGTTTTTAAAGAATATTTTC
AAAAAACCCGGGTTAGGTCAAGGCAGAAATAC
AGAGAGCAGAAACTCATGCCT
TAAGCATTCCAACCAGCATC
AAAAAAGGTACCCGTCAAAACTAGAGAATAATAAAG

a TRO369 hybridizes to the TEF promoter in the NAT1 cassettes and served as a reverse primer in
combination with the confirmational forward primers listed to confirm the mutations.
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Fig 4- 1. The OPI1 gene was disrupted in the strain SC5314 using the CaNAT1FLP cassette .
(A) Structure of the CaNAT1-FLP-OPI1 disruption construct. Approximately 500
base pairs of non-coding DNA flanking the 5’ and 3’ ends of the OPI1 gene (5’and 3’-NCR, respectively) were cloned onto either flank of the CaNAT1-FLP
cassette. The thick dark arrows represent the FRT sites of the FLP recombinase.
The ball-and-stick symbol represents the ACT1 terminator (ACT1t), and the
thinner arrow on a raised line represents the SAP2 promoter (PSAP2). (B) The
OPI1-NAT1 construct used to reintegrate OPI1 into the opi1∆/∆ mutant. (C)
Southern blotting was used to confirm the opi1∆/∆ disruptions. Lanes: 1, wild
type; 2, opi1∆ ::NAT1-FLP/OPI1 strain; 3, opi1∆/OPI1 strain; 4,
opi1∆/opi1∆ ::NAT1-FLP strain; 5, opi1∆/opi1∆ strain; and 6, opi1∆/opi1∆::OPI1
strain.
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Fig 4- 2. The opi1Δ/opi1Δ mutant does not regulate INO1 expression.
Strains were grown for 2 hrs in Medium 199, pH7.0 (± 75 µM inositol) at 37°C,
collected, and subjected to Northern blotting against INO1. ACT1 was reprobed
on the same membrane as a loading control.
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Fig 4- 3. OPI1 -/- mutants exhibited hyperfilamentous growth in filamentinducing conditions on agar plates.
C. albicans strains from overnight cultures were diluted in sterile water and
plated on the indicated medium and grown at 30°C for the indicated amount of
time.
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Fig 4- 4. OPI1 is not required for virulence of C. albicans in a mouse model of
systemic candidiasis.
Each strain was used to infect mice by injecting 106 C. albicans yeast-form cells into
the tail-vein of each mouse. The mice were then assessed for viability over the course
of 14 days.
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Fig 4- 5. OPI1 is involved in establishing infection in the rat vaginitis model.
For each strain 5 rats were inoculated on day 0 with 107 blastospores, and
vaginal cfu were counted by plating at the indicated time points.
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Fig 4- 6. OPI1 affects rat vaginal establishment through regulating SAP2.
For each strain 5 rats were inoculated on day 0 with 107 blastospores, and vaginal cfu
were counted by plating at the indicated time points
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Chapter 5: Conclusions and Discussions
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This thesis revolves around the roles of phospholipid biosynthetic pathways in C.
albicans virulence. Currently, many studies have been concentrated on phospholipids
because they play critical roles in growth, signal transduction, and virulence in addition
to structure components. Our primary goal is to identify genes involved in these pathways
that are required for virulence. The identification of genes involved in virulence may
provide potential drug targets if there is no similar gene in mammalian cells. As
mentioned in chapter 1, the five classes of antifungal drugs currently available have their
own drawbacks such as kidney toxicity and fungal resistance. A new drug could offer an
alternative new therapy to this opportunistic pathogen. Moreover, a new drug could be
given in combination with the other drugs to treat systemic candidiasis even more
efficiently (78).
Three related projects come together to investigate phospholipid metabolism
genes and how they are involved in C. albicans virulence. 1) We have found that unlike
some other pathogens, C.albicans is able to use de novo inositol biosynthesis (INO1) or
import of exogenous inositol (ITR1) with equal efficiency to allow virulence. This is
presumably because either mechanism allows effective synthesis of phosphatidylinositol.
2) The PS synthase gene CHO1 is essential for virulence in mouse model of systemic
candidiasis, as well as cell wall integrity, and mitochondrial function. 3) A putative
regulator of phospholipid metabolism, OPI1, is required for morphogenesis and for
colonization of the vaginal tract in a rat vaginitis model (see Chapter 4). Among the genes
examined in this thesis, CHO1 (phosphatidylserine synthase) is the most promising
candidate for a drug target because there is no similar mammalian gene and this gene is
conserved in opportunistic fungal pathogens including Cryptococcus, Aspergillus, and
non-albican Candida species suggesting a drug with broad spectrum could be developed.
In addition to investigating the virulence, the bacterial pathogen M. tuberculosis
and the parasitic pathogen T. brucei, which both must make inositol de novo in order to
cause disease or even grow, respectively (25, 109, 118). The results showed that inositol
biosynthesis and acquisition in C. albicans is conserved with S. cerevisiae. Interestingly,
the putative inositol regulator OPI1 gene is not conserved with ScOPI1 because OPI1
gene did not regulate expression of the inositol biosynthesis gene INO1 in C. albicans
suggesting inositol regulation between S. cerevisiae and C. albicans has been rewired
(see Chapter 4). This phenomenon is also observed in Yarrowia lipolytica. Hirakawa et al.
demonstrated that Yas3p, an opi1-family transcription factor does not regulate expression
of YlINO1, instead it regulates the expression of YlALK1, an alkane-dependent gene (69).
115

Taken together, the structural INO1 gene is conserved among fungi, and even other
eukaryotes and prokaryotes, but the regulation of the INO1 gene in fungal species has
diverged.
Overall, the thesis suggests that Opi1p and Cho1p could be potential drug targets,
but Cho1p seems to be more promising because cho1Δ/cho1Δ mutants are completely
avirulent and eventually cleared by the host (see Chapter 3). Moreover, Cho1p represents
a new class of targets (phospholipid) for antifungal agents. The more choices of drugs the
more possible weapons to inhibit life-threaten pathogens.
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APPENDICES
APPENDIX E: SUPPLEMENTARY DATA

Table E-1. All C. albicans strains*
Ca genes
OPI1
INO1

CHO1

ITR2

INO1 -/ITR2
PSD1
PSD2
PSD2-/PSD1
OPI3
CHO2

WT
(+/+)
57
(+/+)
57
57
(+/+)
57
57
57
57
(+/+)
57
57
INO1-/ITR2+/+
113
113
(+/+)
57
(+/+)
57
PSD2 -/PSD1 +/+
271
(+/+)
57
(+/+)
57

Hetero-1
(+/-:NAT1)
58
(+/-:NAT1)
100
101
(+/-:NAT1)
132
131
131

Hetero-2
(+/-)
85
(+/-)
105
108
(+/-)
137
135
135

132
137
(+/-:SAT1)
(+/-)
176
185
179
193
INO1 -/INO1 -/ITR2 +/-:SAT1 ITR2 +/180
184
181
187
(+/-:SAT1)
(+/-)
240
247
(+/-:SAT1)
(+/-)
243
250
PSD2 -/PSD2 -/PSD1 +/-::SAT1 PSD1 +/299
300
(+/-:NAT1)
(+/-)
393
400
(+/-:NAT1)
(+/-)
394
401

Homo-1
(-/-:NAT1)
86
(-/-:NAT1)
111
126
(-/-:NAT1)
142
140
191
(-/-:SAT1)
334
(-/-:SAT1)
192
199

Homo-2
(-/-)
88
(-/-)
113

Restored
(-/-:OPI1)
117
(-/-:INO1)
120

Conditional

SAP2 Constitutive
223 (from 57)
226 (from 88)

(-/-:CHO1, MPAr)
172 (partial)
168 (partial)

337
(-/-)
196
201

(-/-::CHO1-SAT1)
344
(-/-:ITR2)
211
INO1-/ITR2-/MET3::ITR2
261
266

(-/-:SAT1)
254
(-/-:SAT1)
257
PSD2-/PSD1-/-::SAT1
373
(-/-:NAT1)
405

(-/-)
280
(-/-)
271
PSD2-/PSD1-/375
(-/-)
406

(-/-:PSD1)
294
(-/-:PSD1)
290
PSD2 -/PSD1 -/MET3::PSD1
331
(-/-:OPI3)
412

*Numbers represent YLC strains
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Fig E-1. The OPI3 gene was disrupted in the strain SC5314 using the SAT1 flipper.
(A) Structure of knock out construct. Approximately 500 base pairs of non-coding DNA
flanking the 5’ and 3’ ends of the OPI3 gene (5’-and 3’-NCR, respectively) were cloned
onto either flank of SAT1 flipper. The thick dark arrows represent the FRT sites of the
FLP recombinase. The ball-and-stick symbol represents the ACT1 terminator (ACT1t),
and the thinner arrow on a raised line represents the MAL2 promoter (PMAL2). (B) The
restored construct used to reintegrate OPI3 into the opi3∆/opi3∆ mutant. (C) Southern
blotting was used to confirm the opi3∆/opi3∆ mutant. (D) opi3∆/opi3∆ mutant did not
exhibit ethanolamine auxotrophy.
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Fig E-2. The CHO2 gene was disrupted in the strain SC5314 using the SAT1 flipper.
(A) Structure of knock out construct. Approximately 500 base pairs of non-coding DNA
flanking the 5’ and 3’ ends of the CHO2 gene (5’-and 3’-NCR, respectively) were cloned
onto either flank of SAT1 flipper. The thick dark arrows represent the FRT sites of the
FLP recombinase. The ball-and-stick symbol represents the ACT1 terminator (ACT1t),
and the thinner arrow on a raised line represents the MAL2 promoter (PMAL2). (B) The
CHO2 conditional expression construct which was used to replace second wild-type
CHO2 allele of CHO2/cho2∆ heterozygote due to inability to obtain cho2∆/cho2∆ mutant.
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Fig E-3. The VPS27, EFG1, CNA1, CNB1, and DPL1 knock out constructs.
Refer A to E for more details.
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Fig E-4. The SAT1-marked MET3 conditional promoter construct was made to test
essential gene.
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Fig E-5. The NAT1-marked construct of constitutive expression under the control of
ACT1 promoter.
The linear plasmids cut by PpuMI or BlpI were transformed and integrated into CaURA3
or ACT1 terminator locus, respectively.
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A

PAct1

Construct

TAct1
PpuM I
EcoR V

TAct1

PAct1
57

223

88

226

B
4.9kb

2.8kb

Fig E-6.The constitutively expression construct of SAP2.
(A) Diagram. (B) Southern blot. The genomic DNA was digested by EcoRV (arrow) and
5’ noncoding region of URA3 was amplified as probe ( asterisk). The strain number 57,
223, 88, and 226 represent C. albicans WT, WT::ACT1::SAP2, opi1Δ/opi1Δ, and
opi1Δ/opi1Δ::ACT1::SAP2, respectively.
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Fig E-7. The cho1∆/cho1∆ mutant formed hyper-wrinkled colonies on YPD containing
medium, both ± serum at 37ºC.
Neither of these effects were observed in the psd1∆/psd1∆ and psd1∆/psd1∆
psd2∆/psd2∆ mutants (data not shown).
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cho1∆ /cho1∆

Length of mitochondrion (µ m)

WT

5
4
3

* (p=0.01)

2
1
0

Fig E-8. The length of mitochondria in cho1∆/cho1∆ mutant might be shorted.
Strains were stained with the vital dye Mitotracker Red CMXRos® after growth to log
phase in YPD at 30ºC.
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Synthetic complete containing 2% glucose
No Etn or Nikkomycin Z

1mM Etn

1mM Etn+10ug/ml Nikko Z

WT
cho1∆/cho1∆
psd1∆/psd1∆
psd1∆/psd1∆ psd2∆/psd2∆
cho1∆/cho1∆::CHO1
psd1∆/psd1∆::PSD1

Fig E-9. The phospholipid mutants were slightly susceptable to chitin synthase inhibitor,
nikkomycin Z.
Strains were grown for 48 hrs at 37ºC.
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YPD
No H2 O2

0.1 mM H2 O2

5 mM H2 O2

WT
cho1∆/cho1∆
psd1∆/psd1∆
psd2∆/psd2∆ psd1∆/pMET3::PSD1
cho1∆/cho1∆::CHO1
psd1∆/psd1∆::PSD1

Fig E-10. Hydrogen peroxide has no observable effects on phospholipid mutants.
Strains were grown for 24 hrs at 37ºC
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YPD
No reagents

10µg/ml Calcofluor White 10µg/ml Congo Red

100µg/ml Hygromycin B

WT
cho1∆/cho1∆
psd1∆/psd1∆
psd2∆/psd2∆ psd1∆/pMET3::PSD1
cho1∆/cho1∆::CHO1
psd1∆/psd1∆::PSD1

Fig E-11. Cell wall perturbating regagents Calcofluor white, CongoHydrogen, and drug
Hygromycin B have no observable effects on the growth of phospholipid mutants.
Strains were grown for 24 hrs at 37ºC.
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YPD
No NaCN/SHAM

1mM NaCN

10mM NaCN

WT
cho1∆/cho1∆
psd1∆/psd1∆
psd1∆/psd1∆ psd2∆/psd2∆

1mM SHAM

5mM SHAM

Fig E-12. 10mM NaCN (inhibiting cytochrome aa3) seems rescue the growth of
phospholipid mutants.
However, SHAM (inhibiting alternative electron transport chain) has no observable
effects on phospholipid mutants. Strains were grown for 42hrs at 37ºC.
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YPD
No Amphotericin B

10µg/ml Amphotericin B

WT
cho1∆/cho1∆
psd1∆/psd1∆
psd1∆/psd1∆ psd2∆/psd2∆

Fig E-13. Amphotericin B has no observable effects on the growth of phospholipid
mutants.
Strains were grown for 48 hrs at 37ºC.
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WT

cho1Δ/cho1Δ

RPMI 1640
+ 1mMEtn

MIC=0.094ug/ml

MIC=0.094ug/ml

Fig E-14. Antifungal fluconazole has no effects on the growth of cho1Δ/cho1Δ mutant.
Strains were grown for 36 hrs at 37ºC.
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YPD/37ºC
WT
WT::ACT1::HOG1 (YLC365)

cho1Δ/cho1Δ
cho1Δ/cho1Δ::ACT1::MKC1 (YLC363)
cho1Δ/cho1Δ::ACT1::HOG1 (YLC371)
WT
WT::ACT1::HOG1 (YLC365)

psd1Δ/psd1Δ
psd1Δ/psd1Δ::ACT1::HOG1 (YLC367)
WT
WT::ACT1::MKC1

psd1Δ/psd1Δ
psd1Δ/psd1Δ::ACT1::MKC1
WT

cho1Δ/cho1Δ
cho1Δ/cho1Δ::ACT1::CNB1 (YLC384)

Fig E-15. The constitutively expression of C. albicans MKC1, HOG1, and CNB1
signaling pathways.
These pathways cannot rescue the growth of mutants’ growth on YPD or YPD
containing sorbitol (data not shown). might not involve in regulating the growth of
phospholipid mutants. Note that constitutively expressionof CNA1 has not obtained.
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Etn free
No Etn/PS

1mM Etn

1µg/ml PS

10µg/ml PS

WT

cho1Δ/cho1Δ

Fig E-16. Phosphatidylserine (PS) can not rescue the growth of cho1Δ/cho1Δ mutant in
our tested condition.
Strains with same concentration were grown overnight in indicated concentration of Etn
or PS at 30ºC.
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Fig E-17. C. albicans Gas1p might be affected in cho1Δ/cho1Δ mutant.
The intensity of Western blot results was normalized by Pma1p. Strains were grown to
log phase at 37ºC and ultra centrifuged (27K & 100K x g) proteins were collected.
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OPI1

+/+

+/-

-/-

-/-::OPI1

SAP2

(OLD)
100% 61%

36%

93%

(NEW)

SAP2
100% 50% 32% 59%

(NEW)

ACT1

Fig E-18. The OPI1 gene affects the transcription of the SAP2 secreted aspartyl protease.
Cells were grown in yeast carbon base (YCB) medium where protein (bovine serum
albumin, BSA) was the only nitrogen source (YCB-BSA) for 12 hours at 37˚C. Total
RNA was isolated, Northern blotted, and probed for the SAP2 gene. Expression levels
were normalized to the ACT1 gene. Note that he old northern blot included serial opi1Δ
mutants obtained from the defective wild type.
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A

B

YCB-BSA plate assay

* 0.008

30

WT

* 0.006

20

SAP2 -/-

+/10

-/-::OPI1

-/0
57

α - sap2

85

88

117

147

strains

Fig E-19. OPI1 -/- mutant exhibits hyper-protease activity in YCB-BSA plate.
(A) Plate assay. (B) quantitative measurement of zones, and western blot results in liquid
YCB-BSA (collected supernatant with anti-sap2p). Asterisks indicate P value as
compared to the wild type.
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Lab solutions:
1. SC+2% glucose (dextrose)
10X YNB 25ml
(1) add 16.75g yeast nitrogen base w/o amino acids
(2) add water to 250ml, then filter sterilize and store at 4ºC
10X Yeast Synthetic drop-out medium supplement w/o uracil 25ml
(1) add 4.8g Yeast synthetic drop-out medium supplement w/o uracil
(2) add water to 250ml, then filter sterilize
10X uracil 25 ml (or uridine for C. albicans)
(1) add 50mg uracil
(2) add water to 250ml, then filter sterilize
40% glucose 12.5ml
Add water to 250ml
SC: Synthetic Complete (YNB + all amino acids)
SD: Synthetic Dextrose (YNB + Dextrose)
2. YCB-BSA-YE (Yeast Carbon Base-Bovine Serum Albumin-Yeast Extract)
2.9g YCB
0.5g
BSA (avoid autoclave; add from filter sterilized 10% BSA stock)
0.25g YE
Add wáter to 200ml  adjust pH  bring water to 250ml.
3. YCB-BSA protease halo (plate) assay
5.8g YCB (Bacto)
10g Agar (Bacto)
Add water to 490ml  autoclave cool down, then add 10ml of 50X BSA stock (10%)
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4. RPMI 1640 for Fluconazole E test strips
5.2g
RPMI 1640 (powder, Cat#50-020-PB,e Cell Gro, w/ L-Glutamine, Phenol Red,
w/out NaHCO3)
17.25g MOPS (0.165mole/L)
9.0g
glucose (note that 1g has already in the powder)
7.5 g Agar (Bacto) (1.5%)
Add water to 450ml  adjust pH from ~5.6 to pH7.0  add water to 500ml
5. M199 medium (pH7.0)
425ml original M199 (9.5g M199, GIBCO Cat#31100-027, Invitrogen,1 pack in 1L water)
75ml 1M HEPES (pH7.0) (150mM HEPES final)
Auto clave.
For making a solid plate, add 10g agar. Note that solid plate (pH4.0) cannot be solidified.
1M HEPES (MW=238.3): add 47.6g of HEPES into 200ml water  adjust pH
6. Spider (Haoping Liu, Science)
5g
Nutrient broth
5g
D-Mannitol
1g
K2HPO4
6.75g Agar (if solid)
Add water to 500ml
7. YPD containing 15% glycerol (for stock in -80ºC)
1g Yeast Extract (1%)
2g Peptone (2%)
2g Dextrose (2%)
Add water to 70ml  add 30ml of 50% glycerol  autoclave
8. Calcofluor White stock (10mg/ml stock)
Add 100mg of Calcofluor White (M2R) to 10ml water
Add 3µl of 10M NaOH to dissolve the powder completely
Filter sterilize  cover with Aluminum Foil and store at 4ºC.
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9. Amphotericin B (10mg/ml stock)
5mg Amphotericin B in 0.5ml DMSO
10. Frequent working concentration in testing C. albicans
Calcofluor White (CFW, 10µg/ml); Congo Red (10µg/ml); Nikkomycin Z (10µg/ml)
Hygromycin B (100µg/ml); Amphotericin B (10µg/ml); Cyclosporin A (100µg/ml);
FK506 (1µg/ml); Fluconazole (100µg/ml); Ketaconazole (50µg/ml); Caffeine (10mM);
Hydrogen Peroxide (1~5mM).
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